The Role of SMAC in NSAID-induced Apoptosis by Bank, Alex
THE ROLE OF SMAC IN NSAID-INDUCED APOPTOSIS 
 
 
 
 
by 
Alexander Bank 
BS, State University of New York at Binghamton, 2000 
 
 
 
 
Submitted to the Graduate Faculty of 
School of Medicine, Department of Pharmacology and Chemical Biology 
in partial fulfillment of the requirements for the degree of 
Doctor of Philosophy 
 
 
 
 
University of Pittsburgh 
2008
UNIVERSITY OF PITTSBURGH 
SCHOOL OF MEDICINE 
 
 
 
This dissertation was presented 
by 
Alexander Bank 
 
It was defended on 
May 21, 2008 
and approved by 
 
 
Robert W. Sobol, Jr., Ph.D. 
Committee Chair 
Department of Pharmacology and Chemical Biology 
 
 
 
Daniel E. Johnson, Ph.D. 
Department of Medicine 
 
 
Yu Jiang, Ph.D. 
Department of Pharmacology and Chemical Biology 
 
 
 
Xiao-Ming Yin, M.D., Ph.D. 
Department of Pathology 
 
 
 
Lin Zhang, Ph.D. 
Thesis Advisor 
Department of Pharmacology and Chemical Biology 
 ii
ABSTRACT 
 
THE ROLE OF SMAC IN NSAID-INDUCED APOPTOSIS 
 
by 
Alexander Bank 
 
Department of Pharmacology and Chemical Biology 
University of Pittsburgh, 2008 
 
 
Nonsteroidal anti-inflammatory drugs (NSAIDs) are effective in cancer 
prevention and have been shown to suppress the formation of colorectal tumors in 
both humans and rodents.  The chemopreventive action of NSAIDs is believed to be 
mediated through induction of apoptosis in preneoplastic cells.  However, the precise 
molecular mechanisms of NSAID-induced apoptosis remain unclear.  Previous 
studies demonstrated that second mitochondria-derived activator of caspase (SMAC) 
plays an important role in executing NSAID-induced apoptosis in colon cancer cells.  
SMAC-knockout HCT116 colon cancer cells are resistant to NSAID-induced 
apoptosis, and are deficient in caspase activation and cytosolic release of cytochrome 
c and apoptosis inducing factor (AIF).  In this study, we tested the hypothesis that 
SMAC regulates the release of cytochrome c and activation of caspase cascade 
through a feed-back amplification loop.  We found that the N-terminal AVPI domain 
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of SMAC is required for the pro-apoptotic activity of SMAC.  Following NSAID 
treatment, SMAC promotes dissociation of caspase-3 from inhibitor of apoptosis 
proteins (IAPs), which in turn leads to mitochondrial dysfunction.  We also studied 
the effects of pharmacological manipulation on NSAID-induced apoptosis by 
employing small molecule compounds that functionally mimic the AVPI domain of 
SMAC.  A synergistic action of NSAIDs and SMAC mimetics was observed in 
inducing a robust apoptotic response in several colon cancer cell lines, as well as in 
NSAID-resistant BAX-KO and SMAC-KO cell lines.  SMAC mimetics appear to 
potentiate NSAID-induced apoptosis by stimulating the release of cytochrome c from 
mitochondria and activation of caspases.  Together, these results suggest that SMAC 
may be useful as a target for the development of more effective chemopreventive 
agents. 
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1 INTRODUCTION 
 
1.1  INTRODUCTION TO CANCER 
  
Human bodies comprise a conglomerate of approximately 50 trillion cells, of 
which there are several billion cells that are actively growing, dividing, and then 
dying in a predictable fashion.  These critical cellular mechanisms are guarded by 
numerous and stringent checkpoints that oversee various aspects of cellular existence 
and together strive to detect and eliminate any aberrant events that might compromise 
the existence of a whole organism.  Cancer can occur when a particular cellular 
pathway loses its ability to effectively control cell growth, cell division or cell death, 
causing uncontrolled cell proliferation and growth.  It is largely believed that cancer 
cells have defects in regulatory circuits that govern normal cell proliferation and 
homeostasis. 
According to the estimates provided by the World Health Organization, there 
are currently 11 million new cases of cancer being diagnosed per year, and this 
number will increase to 16 million by 2020 [1].  There are more than 100 distinct 
types of cancer, and subtypes of tumors can be found within specific organs.  Most 
cancers arise from cells of epithelial origin that cover the body and line internal 
organs.  Cancers of the epithelial cells are categorized as carcinomas, and together 
these malignancies make up about 85% of all cancers, with skin, lung, colon, breast, 
prostate, and uterus being the most frequent sites.  Despite numerous improvements 
in the early detection and treatment of various forms of human cancer, the overall 
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mortality rates for most epithelial cancers have not declined during the last three 
decades [2]. 
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1.2 CANCER INITIATION AND PROGRESSION 
 
Tumor formation involves the progressive, multi-step transformation of 
normal human cells into highly malignant derivatives.  Carcinogenesis can be viewed 
as a process that involves accelerated and abnormal cellular changes in which the 
genes controlling proliferation, differentiation, and cell death are transformed – 
mutated or deleted – in ways that endow the transformed cells with selective growth 
advantages among the environmental pressures of the surrounding tissue [3].  The 
development of a tumor from an initial transformation event follows three distinct 
phases: initiation, promotion, and progression [4, 5].  The initiation phase is a rapid 
and irreversible event that takes place when a normal cell is exposed to a biological, 
chemical or physical carcinogen.  The initial insult to the overall integrity of the 
cellular genome then causes unrepairable or misrepaired DNA damage that is 
reiterated via continued cell division to yield a clone of mutated cells – a second step 
in tumor formation called the promotion phase, during which there occurs an 
expansion of the primary mutated cells to form an actively proliferating, premalignant 
lesion.  During the final progression phase, an additional irreversible event occurs 
within the tumor mass that produces new clones with increased proliferative capacity, 
invasiveness, and metastatic potential [6].  Since the initiation and progression phases 
comprise the irreversible and relatively transient events during the process of tumor 
formation, the promotion phase of carcinogenesis may be most suitable for 
application of cancer preventive strategies [7, 8]. 
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1.3 COLORECTAL CANCER 
 
Colorectal cancer represents a major global health problem and is one of the 
leading causes of cancer mortality in the United States and other developed countries.  
In 2005, colorectal cancer was reported to be the third most common malignancy in 
the United States, with 145,000 newly diagnosed cases that account for almost 12% 
of all newly diagnosed cancers, and the second most lethal malignancy, with 56,000 
deaths that account for about 10% of total cancer deaths [9, 10].  Worldwide, more 
than a million new colorectal cancer cases are diagnosed yearly.  On average, the 
cumulative probability of developing colorectal cancer from birth to age 79 years is 
approximately 4% in men and 3% in women; this probability increases to 5.6% in 
both genders over full-life expectancy [10]. 
As in other systems such as skin cancer, colorectal carcinogenesis has been 
shown to involve many genetics steps [11-14].  The risk of colorectal cancer is much 
higher in patients with a strong family history or genetic mutations that result in an 
increased predisposition for development of colorectal cancer.  The triggering events 
in colorectal carcinogenesis were identified through molecular genetic studies of 
hereditary forms of the disease.  One such hereditary condition is familial 
adenomatous polyposis (FAP), a rare autosomal dominant disease affecting one in 
13,000 births that is associated with an increased risk of colorectal cancer and is 
responsible for 1% of colorectal carcinomas detected in the general population [15, 
16].  FAP was found to be associated with an interstitial deletion on human 
chromosome 5q21 and ultimately caused by a germline inactivation of one allele of 
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the adenomatous polyposis coli (APC) gene, which may be somatically mutated in up 
to a half of all spontaneous colorectal cancer cases [14, 17-19].  The combined 
activities of the APC protein and glycogen synthase kinase-3β lead to 
phosphorylation and subsequent degradation of cytoplasmic β-catenin, which 
functions in establishing cell-to-cell contact through the adherens junctions [20].  
Loss of APC function through germline or somatic mutations of the APC gene results 
in subsequent stabilization of cytoplasmic β-catenin, which undergoes translocation to 
the nucleus and functions as a transcription factor.  Nuclear β-catenin has been 
reported to activate the expression of a number of genes, including c-myc, cyclin D1, 
and MMP-7 [21].  Patients with FAP develop hundreds or even thousands of 
precancerous polyps located in the colon and rectum.  The evolution of a polyp from 
a precancerous stage to invasive cancer takes 4-11 years, and nearly all patients will 
develop colorectal cancer if left untreated (Figure 1.1) [22].  Current treatment 
options for FAP patients primarily involve colectomy – the surgical removal of 
sections or the entire length of the colon, followed by life-long surveillance for 
appearance of new premalignant polyps [23]. 
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Figure 1.1  Colorectal carcinogenesis involves multiple genetic steps. 
Apoptosis is gradually inhibited as precancerous cells in the colonic epithelium lose 
the activity of tumor suppressor genes, including APC and p53, and acquire 
oncogenic mutations, promoting the progression to carcinoma. 
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Recent years afforded increased understanding of the regulation of complex 
molecular events that take place during the course of cancer progression.  Evidence 
for a potential involvement of a group of enzymes called cyclooxygenases (COXs) in 
colorectal cancer was derived from pharmacologic analyses of prostaglandins – 
unsaturated carboxylic acids consisting of a 20-carbon skeleton that also contains a 
five member ring.  Prostaglandins play a central role in inflammation and regulate 
physiologic functions such as gastrointestinal (GI) cytoprotection, vascular 
homeostasis, renal function and blood clotting [16].  Various animal and human 
tumor tissues, including human colon cancer, have been reported to contain high 
concentrations of prostaglandins [24, 25].  Cytoplasmic phospholipase A2, activated 
in response to various stimuli, catalyzes the release of arachidonic acid, the most 
abundant polyunsaturated fatty acid in the phospholipid component of cell 
membranes [26].  Prostaglandins are biochemically synthesized from arachidonic acid 
by several isoforms of cyclooxygenase (COX).  COX-1 and COX-2 are structurally 
distinct, membrane-associated proteins, sharing 60% sequence homology.  While 
COX-1 is constitutively expressed in many tissues, including the gastrointestinal (GI) 
tract, kidneys, and central nervous system, contributing to their homeostasis and 
proper functions, COX-2 is induced in many inflammatory reactions by various 
cytokines, mitogens, growth factors and tumor promoters [27, 28]. 
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1.4 CHEMOPREVENTION OF COLORECTAL CANCER BY 
NONSTEROIDAL ANTI-INFLAMMATORY DRUGS 
 
Early experiments that demonstrated elevated levels of prostaglandin E2 in 
human colorectal tumor tissue as compared to the surrounding mucosa provided the 
rationale for blocking prostaglandin production via the inhibition of COX enzymes as 
a chemoprevention strategy for colorectal cancer [24, 29].  The term 
chemoprevention, originally coined by Michael Sporn in 1976, refers to the use of 
natural or synthetic agents to slow the progression of, reverse, or inhibit the process 
of carcinogenesis, thereby lowering the risk of developing invasive or clinically 
significant disease [2, 7, 30].  Consequently, an effective cancer chemopreventive 
agent should intervene during the early stages of carcinogenesis in order to inhibit the 
initial events that lead to transformation of normal cells and eliminate premalignant 
cells before they reach their malignant potential and pose a health risk to the patient 
(Figure 1.1) [31-33]. 
For this purpose, a group of agents called nonsteroidal anti-inflammatory 
drugs (NSAIDs) were evaluated as potential chemopreventive agents due to their 
general or selective ability to inhibit the activity of COX-1 and/or COX-2, 
subsequently blocking the endogenous biosynthesis of prostaglandins.  The same 
active sites employed by both COX enzymes for binding their natural substrates and 
catalyzing prostaglandin biosynthesis are used by NSAIDs to inhibit their respective 
activities, namely by excluding access for arachidonic acid into the active binding 
channel [34].  The common use of NSAIDs for the control of pain, inflammation and 
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prevention of vascular occlusive diseases has facilitated investigation of the effect of 
these drugs on GI cancer risk.  The use of NSAIDs was found to affect neoplastic and 
non-neoplastic cellular proliferation, tumor growth, and play a role in the control of 
immune response [35-37].  Additionally, the inhibition of COX-1 has been related to 
adverse effects in the GI tract, while inhibition of COX-2 has been more directly 
implicated in reducing inflammation [38].  Selective COX-2 inhibitors were 
subsequently designed that specifically inhibit prostaglandin formation at sites of 
inflammation while sparing the protective effects of COX-1–mediated production of 
prostaglandins on the GI epithelium, reducing the occurrence of potentially dangerous 
and life-threatening side-effects. 
Studies in a variety of rodent animal models (both genetic and carcinogen-
induced) of colon cancer have indicated a significant reduction in the incidence of 
colorectal adenomas and tumors with treatment using NSAIDs [13, 14, 24, 39].  In 
experimental animals transplanted with various tumors, the NSAIDs indomethacin, 
aspirin, and piroxicam were shown to reduce tumor growth [40, 41].  In chemical 
carcinogen-induced rat and mouse tumor models for colorectal cancer, the NSAIDs 
indomethacin, meclofenamate, piroxicam, sulindac, and aspirin were shown to 
significantly decrease the incidence, multiplicity, and/or size of colon tumors in rats 
or mice, and this effect was sometimes observed even many weeks after carcinogen 
challenge [38, 42].  The APCMin/+ mouse has provided an important animal model to 
study the molecular events in colorectal carcinogenesis by recapitulating the features 
of human FAP syndrome.  In the APCMin/+ mouse, the APC gene is disrupted or 
inactivated, leading to the development of gastrointestinal (GI) adenomas by 110 days 
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of age.  Both traditional NSAIDs and selective COX-2 inhibitors have also been 
shown to induce tumor cell death and inhibit tumor development in APCMin/+ mice 
and other murine models of FAP [43-47].  These reports suggest that NSAIDs act to 
suppress tumor formation in the rodents during initiation and/or progression. 
On the basis of the results of the early animal experiments, a number of case 
series and at least 5 randomized clinical trials investigating sulindac administration 
were initiated in FAP patients.  The majority of the clinical studies have proven the 
efficacy of NSAIDs in reducing tumor burden in patients with FAP; sulindac 
produced a statistically significant reduction in both the number and size of the 
polyps in these patients [16].  As in the uncontrolled trials, however, the polyps 
tended to increase in both number and size once sulindac treatment was discontinued.  
Accordingly, sulindac treatment of preoperative FAP patients was not deemed 
complete enough to replace colectomy, although it may be useful as an adjunct to 
surgery in postoperative cases [48, 49].  One of the problems often faced in sulindac 
treatment of FAP patients appears to be the severe side effects that are common to 
NSAIDs, e.g., bleeding and ulceration.  Although some patients tolerate sulindac 
without such problems, its side effects can be serious, even fatal, in others.  For this 
reason, there has been a strong effort to develop new therapeutic agents that lack 
these side effects, such as selective COX-2 inhibitors. 
Another line of evidence for the inhibition of colorectal tumorigenesis by 
NSAIDs came from a large number of epidemiologic studies, which were encouraged 
by the animal and FAP studies.  These epidemiologic studies, including Cancer 
Prevention Study II (662,424 patients) and Health Professionals Follow-Up Study 
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(47,900 men), have documented up to 50% reduction in colorectal adenomas, 
colorectal cancer, and colorectal-associated mortality in individuals regularly taking 
NSAIDs (ex. aspirin) [16].  Also, there was an indication of a strong protective effect 
of NSAIDs (primarily aspirin) on the occurrence of adenomatous polyps and the 
incidence of mortality from colorectal cancer [16].  
In studies analyzing the effect of NSAIDs in high-risk patients with recurring 
colorectal cancer, the rate of recurrence of adenomas was significantly lower in the 
patient group taking lower-dose aspirin (81 mg/d) than in the placebo group, whereas 
the larger dose of aspirin (325 mg/d) did not significantly reduce the rate of 
recurrence, indicating that low-dose aspirin may have some benefit in reducing the 
risk of recurrent adenomas among persons with a history of colorectal cancer or 
adenomas (both doses of aspirin appeared to reduce the levels of colorectal 
prostaglandins to a similar extent) [50-52].  Results from these and many other 
observational studies strongly support the hypothesis that NSAIDs inhibit the 
incidence, progression, and death due to colorectal cancer.  These benefits do not 
appear to be influenced by study design, specific NSAIDs, or patient characteristics 
including age, gender, and nationality. 
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1.5 APOPTOSIS AS A MECHANISM OF COLORECTAL CANCER 
CHEMOPREVENTION BY NSAIDS 
 
During more than 30 years of pre-clinical and clinical research, NSAIDs have 
been shown to exert several effects in a variety of malignancies that may contribute to 
a broad spectrum of chemopreventive activities at different stages of carcinogenesis 
[53].  Numerous published reports of experiments on animal models, epidemiologic 
studies, and clinical trials indicate that NSAIDs can slash the incidence of colorectal 
cancers in human and experimental animals and can reduce the number and size of 
polyps in patients with FAP [54].  A number of population-based studies have 
detected a 40-50% decrease in the relative risk of colorectal cancer in persons who 
regularly use aspirin and other NSAIDs [27, 36, 55, 56].  Randomized secondary 
prevention and primary prevention trials in high-risk patients have clearly 
demonstrated that NSAID treatment caused regression of preexisting adenomas [37, 
57]. 
Initial attempts to elucidate the molecular basis of NSAID-mediated anti-
cancer action in colorectal chemoprevention led to observations that both human and 
animal colorectal tumors express high levels of COX-2, whereas the normal intestinal 
mucosa has low to undetectable levels of COX-2 expression, leading to the 
hypothesis that COX-2 may be playing a role in colon cancer and progression [58, 
59].  Both in vitro and in vivo studies have demonstrated that proliferation of human 
colon cancer cell lines was inhibited by treatment with a highly selective COX-2 
inhibitor in tumors that express COX-2, but not in those that lack COX-2 expression 
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[60, 61].  Additionally, when the COX-2 gene was inactivated in APCMin/+ mice, both 
the number and the size of polyps were reduced dramatically, while inhibition of 
COX-2 expression was associated with reduced development of GI malignancy in 
humans and in animal models of colorectal cancer [62].  
Despite a wealth of experimental and clinical data favoring the role of COX 
inhibition as the primary effect of NSAID-induced chemopreventive action, 
accumulating evidence suggests that aspirin and other traditional, non-selective 
NSAIDs may exert their effects by COX-independent mechanisms, such as the ability 
of NSAIDs to restore apoptotic cell death in colon cancer cells, inhibition of nuclear 
factor-κB or interference with the binding of the nuclear peroxisome-proliferator 
activated receptor δ to DNA [43, 63-68].  In favor of this notion, one of the major 
metabolites of an extensively studied chemopreventive NSAID sulindac, sulindac 
sulfone has been reported to be at least 5,000 times less potent than sulindac sulfide at 
inhibiting prostaglandin synthesis while retaining the ability to induce apoptosis in 
various cell types to approximately same degree [66, 69-71].  However, the specific 
mechanisms of these COX-independent effects and their therapeutic implications are 
not yet well understood. 
Several animal studies have demonstrated that a number of chemopreventive 
agents exhibit the ability to induce apoptosis in various types of tumor cells.  In the 
APCMin/+ mouse model of human colorectal cancer, aspirin decreased the spontaneous 
rate of colon tumor formation by 44% and normalized the growth of enterocytes, the 
differentiated epithelial cells located in the lining of the intestinal mucosa that 
participate in absorption, by increasing apoptosis and reducing the proliferation of 
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preneoplastic intestinal mucosa cells [46].  The chemopreventive properties of dietary 
administration of sulindac were associated with a significant induction of apoptosis in 
colon tumor cells, combined with an overall increase in the number of apoptotic cells, 
in a rat model of chemical carcinogen-induced colon cancer [72].  
Human chemoprevention trials have also demonstrated an association between 
a clinical response to NSAIDs and the induction of apoptosis in tumor cells [73-75].  
Increased apoptosis in colorectal polyps was observed in a phase I clinical trial that 
studied the chemopreventive properties of the NSAID sulindac sulfone in FAP 
patients and another study examining the chemopreventive effects of the NSAID 
mesalazine in colorectal cancer patients [73, 75].  Both agents did not affect cellular 
proliferation in the malignant and normal tissue samples, indicating the apparent 
selectively in apoptosis induction in tumor cells by NSAIDs. 
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1.6 MECHANISM OF APOPTOSIS 
 
One of the earliest observations of apoptosis induction in cancer cells came 
from the landmark study investigating the effects of etoposide [76].  Since then, 
evidence supporting the role of apoptosis in chemotherapy action continues to 
accumulate [77].  Apoptosis represents a regulated cell suicide program that is 
distinct from necrosis and is essential for organism development and for adult tissue 
homeostasis [78].  The initiation of apoptosis can be highly dependent on cell type 
and nature of the particular apoptosis stimulus.  The typical morphologic markers 
used to identify a cell that is actively undergoing apoptosis include DNA 
fragmentation, chromatin condensation, cell shrinkage, plasma membrane ‘blebbing’, 
loss of cell surface features, detachment from the basement membrane and its 
neighbors, and externalization of phosphatidylserine to the outer leaflet of plasma 
membrane (signaling for phagocytic cells to engulf the dying cell).  These dramatic 
changes are mediated through the cell-wide activation of cellular hydrolases that 
include a family of proteases called caspases as well as nucleases that participate in 
the degradation phase of apoptosis through the cleavage of proteins and DNA [79].  
Caspases represent a family of cysteine-containing aspartate-specific proteases that 
are initially present in the cell as inactive proenzymes and are subsequently activated 
by cleavage at specific aspartate cleavage sites.  The N-terminal pro-domain of 
caspases is released, while the remaining two subunits form an active heterodimer.  
The activation of caspases often occurs in a sequential fashion.  The family of 
caspases can be subdivided into initiators (caspase-2, caspase-8, caspase-9) and 
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executioners (caspase-3, caspase-6, caspase-7).  During the progression of apoptosis, 
the cell separates into membrane-bound fragments called apoptotic bodies without 
releasing cellular components into surrounding tissues, thus avoiding the initiation of 
an inflammatory response to the dying cell.  In the colon, apoptotic cells can be 
sloughed into the lumen or the apoptotic bodies can be engulfed by adjacent 
colonocytes or macrophages in the lamina propria [80]. 
A wealth of research effort currently supports the notion that the mechanism 
of apoptotic cell death is controlled via two major pathways, one that originates at the 
death receptors on the plasma membrane – termed the extrinsic pathway, and another 
that originates at the mitochondria – termed the intrinsic pathway (Figure 1.2).   
The activation of the extrinsic pathway of apoptosis takes place at the cell 
surface when a specific cell surface death receptor, including tumor necrosis factor 
receptor (TNFR), TNF-related apoptosis-inducing ligand (TRAIL) receptor, and Fas, 
is activated by binding to its corresponding ligand molecule(s).  Following ligand 
binding, there is a trimerization of death receptors at the plasma membrane that 
subsequently promotes the recruitment of adapter proteins, including FADD and 
RIP1 [81].  The interaction between the adapter proteins, recruited to the activated 
death receptors, and the zymogen form of caspase-8 results in activation of caspase-8 
and activation of downstream caspases, including caspase-3, which may or may not 
be sufficient to initiate the proteolytic cascade that results in apoptotic cell death, 
depending on the cell type [79, 81]. 
The intrinsic pathway, associated with most pro-apoptotic stimuli, relies 
solely on the permeabilization of the mitochondrial membrane and is controlled by 
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the carefully coordinated actions of pro- and anti-apoptotic members of the Bcl-2 
family, including pro-apoptotic BAX and Bad, and anti-apoptotic Bcl-2 and Bcl-XL.  
During conditions of cell stress, the ratio of pro-apoptotic Bcl-2 family members to 
anti-apoptotic Bcl-2 family members increases, leading to destabilization of the anti-
apoptotic Bcl-2 family members present in the outer mitochondrial membrane and the 
formation of pores or channels in the outer mitochondrial membrane [82, 83]. 
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Figure 1.2  Mechanisms of apoptosis. 
In the extrinsic pathway, activation of a death receptor by ligand binding leads to 
cleavage and activation of initiator caspase-8.  In the intrinsic pathway, activation of 
pro-apoptotic proteins results in a release of cytochrome c, which interacts with Apaf-
1 and procaspase-9 to form the apoptosome that cleaves and activates caspase-9.  
Activation of caspase-8 or -9 activates executioner caspase-3 [84]. 
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Activation of the intrinsic apoptotic pathway leads to the cytosolic release of 
several mitochondrial apoptogenic proteins that normally reside in the inter-
membrane space of the mitochondria prior to initiation of apoptosis.  Once in the 
cytosol, these proteins can trigger either the activation of the caspase cascade or 
activation of caspase-independent cell death pathways [85, 86].  Mitochondrial 
proteins that cause caspase-dependent cell death include cytochrome c, SMAC/Diablo 
and HtrA2/Omi.  The cytosolic form of cytochrome c interacts with apoptosis 
protease activating factor-1 (Apaf-1) and the zymogen form of caspase-9 to form a 
trimeric complex called an apoptosome that subsequently recruits additional pro-
caspase molecules and ultimately triggers global activation of the caspase cascade 
[87].  SMAC and HtrA2/Omi potentiate caspase activation by binding inhibitor of 
apoptosis proteins (IAPs) and blocking their caspase inhibitory activity [88-91].  
Mitochondrial proteins that participate in caspase-independent cell death include 
apoptosis-inducing factor (AIF) and endonuclease G (EndoG).  Both AIF and EndoG 
undergo nuclear translocation after being released from the mitochondria, where they 
participate in inducing chromatin condensation and large-scale DNA fragmentation 
[92].  In addition to mitochondria, it is believed that additional subcellular organelles, 
including the endoplasmic reticulum, Golgi apparatus, and lysosomes, may 
participate in damage sensing, pro-apoptotic signaling, and caspase activation [93]. 
There exist several models that attempt to delineate the precise molecular 
events that result in the release of mitochondrial proteins.  In one model, the 
mitochondrial permeability transition (MPT), characterized by increased permeability 
of the mitochondrial membranes, occurs as a result of opening of mitochondrial 
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permeability transition pores that are formed in the membranes of mitochondria under 
certain pathological conditions and leads to mitochondrial swelling and ultimately 
cell death [86, 94, 95].  According to another model, pro-apoptotic Bcl-2 proteins like 
BAX and/or Bak induce outer-membrane permeabilization through the formation of 
channels or pores, thus allowing the release of mitochondrial apoptogenic proteins 
[85, 96, 97].  
Recent evidence has revealed the ability of several chemopreventive agents, 
including NSAIDs, to induce apoptosis in a variety of premalignant and cancer cell 
types.  The chemopreventive effects of NSAIDs were originally envisioned to involve 
the inhibition of COX enzymes, resulting in modulation of cellular pro-inflammatory 
prostaglandin synthesis.  Presently, there is a change in the prevailing view of how 
NSAIDs manifest their anticancer effects, with a shift towards appreciating the role of 
apoptogenic effects of these agents that are independent of their COX inhibitory 
activities – COX-2 selective celecoxib and nonselective sulindac can both induce 
apoptosis in COX-2–deficient cells, arguably through COX-2–independent 
mechanisms, and activate caspases through intrinsic effector mechanisms that are 
regulated by Bcl-2 family members or the mitochondrial permeability transition.  At 
the same time, there are data suggesting that sulindac may also employ extrinsic 
effectors in addition to its ability to engage the intrinsic effects, necessitating further 
research into the precise mechanism of apoptosis induced by NSAID treatment [98]. 
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2 MATERIALS AND METHODS 
 
2.1 CELL CULTURE 
The colorectal cancer cell lines used in the study, including HCT116, HT29, and 
DLD1, were obtained from American Type Culture Collection.  SMAC-knockout 
(SMAC-KO) and BAX-knockout (BAX-KO) HCT116 cell lines were previously 
described [71, 99].  All cell lines were cultured in McCoy’s 5A media (Invitrogen) 
supplemented with 10% defined fetal bovine serum (Hyclone), 100 units/mL 
penicillin, and 100 mg/mL streptomycin (Invitrogen) and were maintained at 37°C in 
5% CO2.  SMAC-reconstituted SMAC-KO cell lines were generated by transfecting 
SMAC-KO cells with wild-type (AVPI) or mutant SMAC (ΔA), followed by selection 
in 0.4 mg/mL G-418 (Invitrogen) [100]. 
 
2.2 DRUG TREATMENT 
To induce apoptosis, cells were plated at 20% to 30% density in 12-well plates and 
allowed to attach overnight.  DMSO stock solutions of sulindac sulfide (Merck) at 40 
mmol/L and indomethacin (Sigma) at 100 mmol/L were freshly prepared and diluted 
into appropriate concentrations by cell culture medium.  Different concentrations of 
sulindac and indomethacin were used for apoptosis induction in different colon 
cancer cell lines and were determined based on their dose responses.  The SMAC 
mimetic and control compounds, C3 and C4, respectively, were provided by Dr. 
Xiaodong Wang and Dr. Patrick G. Harran at University of Texas Southwestern 
Medical Center.  An independent set of SMAC mimetic test (GT-T) and control (GT-
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C) compounds were supplied by TetraLogic Pharmaceuticals.  All compounds were 
prepared as 100 μmol/L stock solutions in DMSO.  In some cases, caspase-3 inhibitor 
Z-DEVD-fmk (20 μmol/L; R & D Systems) was used to treat cells in combination 
with the agents described above. 
 
2.3 WESTERN BLOTTING 
The antibodies used for Western blotting included those against caspase-9, Bid (Cell 
Signaling Technology), cytochrome c, α-tubulin (BD Biosciences), caspase-3 
(Stressgen Bioreagents), cytochrome oxidase subunit IV (COX IV; Invitrogen), Bim, 
and SMAC (EMD Biosciences).  Western blotting analysis was performed as 
previously described [101].  Briefly, cell lysates resuspended in 2 × Laemmli sample 
buffer were heated 95°C for 20 min and loaded onto a 10-well or a 12-well pre-cast 
NuPAGE® 10% Bis-Tris gel (Invitrogen).  The gels were run in a Novex Xcell 
SureLock mini-cell gel apparatus (Invitrogen); the inner chamber was filled with 200 
mL NuPAGE MES SDS running buffer (Invitrogen) containing 500 μL NuPAGE 
antioxidant (Invitrogen), while the outer chamber was filled with 300 mL NuPAGE 
MES SDS running buffer alone.  The proteins were resolved at constant voltage.  
Prior to transfer, the Immobilon-P (pore size: 0.45μm) transfer membrane (Millipore) 
was briefly washed with methanol, rinsed with deionized water and equilibrated in 
Tris-Glycine transfer buffer (48 mmol/L Tris base, 40 mmol/L glycine, 20% 
methanol, 0.04% SDS).  The gels were transferred at constant current. 
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2.4 IMMUNOPRECIPITATION 
Following drug treatment, the cells were harvested by gently scraping with a rubber 
policeman and resuspended in 1 mL of EBC buffer (50 mmol/L Tris-HCl, pH 7.5, 
100 mmol/L NaCl, 0.5% Nonidet P-40) supplemented with protease inhibitor mixture 
(Roche Applied Sciences).  The cells were disrupted by sonication and then spun at 
10,000 × g for 10 min to collect the cell lysates.  For immunoprecipitation (IP), 1-2 
μg of IP antibodies were added to 50 μL cell lysates.  The mixtures were mixed on a 
rocker at 4°C overnight.  The immunocomplexes were captured by the addition of 
protein G/A-agarose (Roche Applied Sciences) mixed at 1:5 ratio, followed by 
incubation at 4°C for 1 hour.  The beads were washed four times by EBC buffer and 
then collected by centrifugation at 6,000 × g.  After the final wash, the beads were 
mixed with 50 μL of 2 × Laemmli sample buffer, heated at 95°C for 15 min, and 
analyzed by Western blotting. 
 
2.5 NUCLEAR AND CYTOSOLIC FRACTIONATION 
Nuclear and cytosolic fractions were isolated from treated cells using Pierce NE-PER 
kit (Pierce, #78833) according to the manufacturer’s instructions. 
 
2.6 APOPTOSIS ASSAYS 
After treatment, attached and floating cells were harvested at various time points.  
The fractions of apoptotic cells were evaluated by nuclear staining and Annexin 
V/propidium iodide staining.  For nuclear staining, cells were fixed in a solution 
containing 3.7% formaldehyde, 0.5% Nonidet P40, and 10 μg/mL 4’,6-diamidino-2-
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phenylindole dihydrochloride in PBS and assessed for apoptosis through microscopic 
visualization of condensed chromatin and micronucleation.  For each measurement, at 
least three independent experiments and a minimum of 300 cells were analyzed.  For 
Annexin V/propidium iodide staining, cells were stained by propidium iodide and 
then Annexin V-Alexa 594 (Invitrogen) according to the manufacturer’s instructions.  
Flow cytometry was used to quantitate Annexin V–positive and propidium iodide–
positive cells.  Annexin V protein conjugated with a fluorochrome allows for the 
detection of phosphatidylserine that is translocated from the inner leaflet to the outer 
leaflet of the plasma membrane during induction of apoptosis.  Propidium iodide only 
stains non-viable cells and becomes highly fluorescent upon binding of DNA. 
 
2.7 COLONY FORMATION ASSAY 
Long-term cell survival was evaluated by colony formation assays.  In brief, cells 
were plated in a single 75-cm2 flask.  Following treatment, cells were harvested by 
trypsinization and plated in 12-well plates at appropriate dilutions.  Cells were 
allowed to grow for 10 to 14 days before staining with Crystal Violet (Sigma). 
 
2.8 CELL VIABILITY ASSAY 
The MTS cell proliferation assay is a colorimetric method for determining the number 
of viable cells in proliferation.  It is composed of solutions of a tetrazolium compound 
[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium, inner salt; MTS] and an electron coupling reagent (phenazine 
ethosulfate; PES).  MTS is reduced by mitochondrial activity inside the cells into 
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formazan product that is soluble in cell culture medium.  Cells were plated in 96-well 
tissue culture plates.  Following treatment, cells were incubated with 20 μl of MTS 
(2.5 mg/mL: Sigma Chemical Co) stock solution in each well.  After 30 min 
incubation under standard conditions of 5% CO2 and 37°C, the absorbance was read 
on PerkinElmer Victor3 plate reader at 490 nm.  The signal generated (color 
intensity) is directly proportional to the number of viable (metabolically active) cells 
in the wells. 
 
2.9 ANALYSIS OF CYTOCHROME C RELEASE 
Mitochondrial and cytosolic fractions were isolated from treated cells by differential 
centrifugation as previously described [102].  Briefly, a single 75-cm2 flask of cells 
was harvested after one wash with Hanks buffer at 4°C.  Whole-cell pellets were 
resuspended in homogenization buffer (0.25 mol/L sucrose, 10 mmol/L Hepes, pH 
7.4, 1 mmol/L EGTA) and subjected to 40 strokes in a 2-ml Dounce homogenizer on 
ice.  The homogenates were subjected to centrifugation at 1,000 × g for 15 min at 4°C 
to pellet nuclei and unbroken cells.  The supernatant was subsequently subjected to 
centrifugation at 10,000 × g for 15 min at 4°C to obtain cytosolic fractions 
(supernatant) and mitochondrial fractions (pellet).  Mitochondrial pellets were 
resuspended in homogenization buffer following one wash with homogenization 
buffer at 10,000 × g for 15 min at 4°C.  The concentrations of cytosolic fractions 
obtained from different samples were normalized using protein assay dye reagent 
from Bio-Rad.  All fractions were mixed with equal volumes of 2 × Laemmli sample 
buffer for Western blotting analysis. 
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2.10 RNA INTERFERENCE 
RNA interference is a technique whereby protein synthesis is prevented through 
silencing of the gene-specific mRNA and ultimate inhibition of protein translation.  
Two caspase-3 small interfering RNA (siRNA) duplexes (Cas-3 986, 5’-UGA GGU 
AGC UUC AUA GUG Gtt-3’; Cas-3 182, 5’-TGA CAT CTC GGT CTG GTA Ctt-
3’) were previously characterized [103, 104] and purchased from Dharmacon, Inc., as 
20 μmol/L stock solutions.  Cells were transfected with siRNA at 100nmol/L final 
concentration by Lipofectamine 2000 (Invitrogen) according to the manufacturer’s 
instructions.  Down-regulation of caspase-3 expression was verified by Western 
blotting. 
 
2.11 STATISTICAL ANALYSIS 
Statistical analyses were performed using GraphPad Prism IV software.  The averages 
± 1 standard deviation were displayed in the figures. 
 26
3 THE ROLE OF THE BCL-2 FAMILY MEMBERS BAX, 
BCL-XL AND MCL-1 IN NSAID-INDUCED APOPTOSIS 
 
3.1 INTRODUCTION 
 
Among many described activities of NSAIDs, induction of apoptosis 
secondary to inhibition of COX enzymes seems to play a critical role in NSAID-
mediated chemoprevention [105-107].  Apoptosis is a major mechanism regulating 
turnover of intestinal epithelial cells from which colon tumors are derived [108].  
During the formation of a colon tumor, apoptosis is progressively inhibited due to 
oncogenic mutations [109].  Deregulation of apoptosis is necessary for oncogenic 
transformation and drives neoplastic cells to gain additional tumorigenic features 
[110].  NSAIDs have been found to induce apoptosis in colon cancer cells in vitro and 
in vivo [105, 106].  The apoptotic level can be used as a biomarker for NSAID-
mediated chemoprevention [72, 111].  Furthermore, it has been shown that NSAID 
treatment can reverse the anti-apoptotic effects of COX-2 [63]. 
Numerous cell line and animal studies have provided a solid foundation for 
the role of Bcl-2 family proteins in playing a critical and fundamental role in 
controlling the pivotal aspects of cellular life and death [112].  The initial discovery 
of mammalian regulators of apoptotic cell death emerged from the studies focused on 
the genetic changes that occur during the development of human follicular 
lymphoma.  The cloning of the chromosomal breakpoint present in the chronic 
lymphocytic leukemia cells revealed a translocation of the long arms of chromosomes 
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11 and 14, resulting in an overabundant activation of the Bcl-2 gene [113].  It was 
subsequently shown that the product of the Bcl-2 gene permitted the survival of 
cytokine-dependent hematopoietic cells under cytokine withdrawal culture conditions 
[114].  The observations that followed together led to the development of a model in 
which cell survival and proliferation were controlled by distinct and separate genetic 
pathways regulated by members of the Bcl-2 family, with some members such as Bcl-
2 and Bcl-XL inhibiting cell death and others such as BAX inducing cell death. 
All Bcl-2 family members possess at least one of four conserved motifs 
known as Bcl-2 homology domains (BH1 to BH4) and can be subdivided into 
"multidomain" and "BH3-only" groups.  The multidomain proteins contain three or 
four BH domains, while the BH3-only proteins display sequence homology with other 
members only within an α-helical BH3 domain, which is essential for apoptosis 
induction [115].   Pro- and anti-apoptotic family members can form heterodimeric 
complexes through associations between their respective BH1, BH2, and BH3 
homology domains.  These interactions have an overall effect of regulating each 
other’s function, suggesting that the relative abundance of pro-survival versus pro-
apoptotic proteins may act as a rheostat for the suicide program [116].  The 
alterations in the ratio between pro-apoptotic and anti-apoptotic members of the Bcl-2 
family can determine the sensitivity of a cell to induction of apoptosis [95]. 
It is well known that NSAIDs inhibit cyclooxygenase-2 (COX-2) and other 
enzymes.  However, the mechanisms underlying the anti-neoplastic effects of 
NSAIDs are currently unclear.  Experimental data has implicated the involvement of 
apoptotic cell death induction as a plausible mechanism behind NSAID-mediated 
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chemopreventive effects.  In mammalian cells, apoptosis induced by anticancer 
agents is often mediated through mitochondria by the Bcl-2 family proteins.  In this 
pathway, pro-apoptotic Bcl-2 family proteins, such as BAX, mediate the release of 
cytochrome c from the mitochondria, which triggers the caspase activation cascade 
and other events in apoptosis.  Anti-apoptotic Bcl-2 proteins, including Bcl-2, Mcl-1 
and Bcl-XL, inhibit apoptosis presumably through the formation of heterodimers with 
pro-apoptotic proteins, thus preventing their activation and the subsequent release of 
cytochrome c.   
The involvement of pro-apoptotic BAX and anti-apoptotic Bcl-XL in 
anticancer effects of NSAIDs has been recently explored in human colon cancer cell 
lines [71].  These studies, facilitated by the development of a BAX knock-out cell line, 
initially indicated that BAX-deficient HCT116 cells displayed a dramatic resistance 
to the induction of apoptosis when treated with up to 200 μmol/L sulindac, as 
evidenced by lack of apoptotic markers, including chromatin condensation, nuclear 
fragmentation, and annexin-V/PI positivity, that typically occur in wild-type HCT116 
cells treated with 120 μmol/L sulindac [71].  Furthermore, it was discovered that the 
prolonged exposure of HCT116 cells to NSAID treatment resulted in clonal selection 
and expansion of multiple NSAID-resistant subpopulations of cells.  These NSAID-
resistant cells have acquired (presumably inactivating) mutations, characterized by 
insertions or deletions, within the BAX gene, bestowing selective growth advantage to 
cells with a defective BAX gene as compared to cells that carried a wild-type BAX 
gene and hence retained the ability to initiate and carry out apoptotic cell death in 
response to NSAID treatment. 
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While NSAID treatment did not induce any changes in BAX mRNA 
expression or protein levels, the expression of Bcl-XL was substantially reduced by 
NSAID treatment.  The downregulation of Bcl-XL by NSAIDs coincided with the 
appearance of apoptotic markers including cleaved caspase-3 and nuclear 
fragmentation, indicating the significance of the ratio between pro-apoptotic BAX 
and anti-apoptotic Bcl-XL in regulating NSAID-induced apoptosis [71].  Expression 
of ectopic Bcl-XL rescued HCT116 cells with an intact BAX gene from NSAID-
mediated apoptosis and enhanced long-term survival and colony formation ability, 
indicating the role of Bcl-XL in mediating resistance to the apoptotic cell death 
program.  Together, the significance of BAX and Bcl-XL during apoptosis induced by 
NSAIDs reinforces the overall importance of the stoichiometric ratio among pro-
apoptotic proteins and anti-apoptotic proteins for proper control over the cellular 
propensity to either resist or undergo apoptosis following chemotherapeutic 
treatment. 
Acquired resistance to chemotherapy is an important factor that negatively 
influences the success of cancer treatment and a crucial determinant of the ultimate 
outcome of cancer treatment [117, 118].  There are various mechanisms responsible 
for cancer cell chemoresistance, such as modification of drug-target interactions, 
decreased uptake or increased elimination of active drug molecules, and apoptosis 
defects.   The evasion of apoptosis is a critical component of oncogenic 
transformation and chemotherapy resistance.  Cancer cells may escape from apoptosis 
in response to various stimuli, such as chemotherapy and radiotherapy, through 
overexpression of anti-apoptotic Bcl-2 protein family members or loss of pro-
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apoptotic Bcl-2 protein family members.  An elevated level of anti-apoptotic proteins 
of the Bcl-2 protein family, including Bcl-2, Bcl-XL, Bcl-w, Mcl-1 and Bfl-1, has 
been shown to negatively affect the outcome of chemotherapy in various tumor types 
[119]. 
In addition to its apparent ability to engage a BAX-dependent mitochondrial 
pathway of apoptosis in colon cancer cell lines, sulindac has been recently 
demonstrated to engage the death receptor pathway of apoptosis via the induction of 
death receptor 5 (DR5) expression [98].  Following ligand binding (ex. TRAIL), 
death receptors, including DR5, form homotrimers that signal through the adaptor 
protein FADD, which subsequently recruits caspase-8.  Activation of caspase-8 
initiates downstream caspase cleavage events.  The human colon cancer cell line 
HCT116 shows a type II response to activation of the extrinsic apoptotic pathway and 
requires activation of caspase-9 for TRAIL-induced apoptosis.  Previous studies have 
demonstrated that death receptors can be activated in a ligand-independent manner 
when the levels of death receptors are increased through endogenous induction or 
exogenous overexpression.  Forced overexpression of DR5, independent of the levels 
of its ligand, has been shown to induce apoptosis [120].  These findings raise the 
possibility that sulindac may activate DR5 to induce apoptosis in colon cancer cells in 
a ligand-independent manner. 
An additional mechanism of apoptosis resistance in BAX-deficient HCT116 
cells has been recently demonstrated.  Experiments using TRAIL treatment in 
HCT116 wild-type and BAX-KO cells indicated that TRAIL induces NF-κB–
mediated expression of the anti-apoptotic Mcl-1 protein specifically in TRAIL 
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resistant BAX-KO cells [121].  Overexpression of Mcl-1, first identified as an ‘early 
induction’ gene during differentiation of the myeloid cell line ML-1, prolongs the 
survival of cells exposed to a variety of apoptosis-inducing stimuli, including 
cytokine withdrawal, staurosporine, etoposide, and UV irradiation, while depletion of 
Mcl-1 facilitates entry into apoptosis [122].  The ability of TRAIL to induce Mcl-1 
appeared to necessitate the suppression of the mitochondrial pathway of apoptosis, as 
illustrated by inhibition of caspase-9 activity, overexpression of Bcl-XL, or BAX 
deficiency [121].  Inhibition of TRAIL-induced expression of Mcl-1, through 
combination of TRAIL treatment with either ectopic expression of c-Myc or 
treatment with the multikinase inhibitor sorafenib, significantly sensitized BAX-KO 
cells to TRAIL-induced apoptosis, suggesting a possible mechanism of overcoming 
resistance to cell death signaling in these cells.  In this study, the functional role of 
Bcl-XL and its interaction with the pro-apoptotic protein BAX was investigated in 
apoptosis induced by NSAIDs in colon cancer cells.  Additionally, the role of Mcl-1 
in mediating additional resistance to NSAIDs was investigated. 
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3.2 RESULTS 
 
 
3.2.1 NSAIDS INDUCE PROTEASOMAL DEGRADATION OF 
ANTI-APOPTOTIC BCL-XL 
 
To establish the effects of NSAIDs on the anti-apoptotic Bcl-2 family member 
Bcl-XL, HCT116 cells and the BAX-knockout (BAX-KO) cells were subjected to 
treatment with 500 μmol/L indomethacin for up to 24 hours.  In HCT116 cells, a 
time-dependent degradation of Bcl-XL occurred that resulted in approximately 50% 
reduction in Bcl-XL levels after a 24 hour indomethacin treatment (determined by 
densitometry analysis of protein band intensity on the developed film) (Figure 3.1), 
confirming the published results [71].  The same effect was not evident in the BAX-
KO cells, suggesting that Bcl-XL degradation induced by indomethacin requires the 
presence of the BAX gene (Figure 3.1). 
A wide variety of cellular proteins undergo proteolytic degradation catalyzed 
by the ubiquitin-proteasome pathway.  A small molecule proteasome inhibitor PS-341 
was used, at non-cytotoxic concentrations, to determine whether Bcl-XL degradation 
is mediated by the proteasome in HCT116 cells.  A time-dependent accumulation of 
Bcl-XL was observed when cells were treated with PS-341 at two different 
concentrations, in agreement with the proposed proteasome-mediated degradation of 
Bcl-XL in healthy cells (Figure 3.2A).  The process of covalent protein poly-
ubiquitination serves as a critical signaling event for a multitude of cellular proteins 
to be degraded as a means of regulating protein half-life and stability.  To determine 
 33
whether ubiquitin is conjugated onto Bcl-XL protein during NSAID treatment, 
HCT116 cells were transiently co-transfected with HA-tagged ubiquitin and V5-
tagged Bcl-XL plasmids for 12 hours, and subsequently treated with sulindac for up to 
24 hours.  Whole cell lysates were collected at specified time points, and exogenous 
Bcl-XL was immunoprecipitated with a V5 antibody.  Since protein ubiquitination 
represents a covalent modification, the immunoprecipation lysates were analyzed on a 
typical denaturing SDS-PAGE gel.   Immunoprecipitation of exogenously expressed 
V5-tagged Bcl-XL indicated an appearance of high molecular weight bands believed 
to represent mono- and poly-ubiquitinated Bcl-XL species (Figure 3.2B).  Treatment 
with sulindac caused an accumulation of high molecular weight Bcl-XL–ubiquitin 
complexes, which was enhanced by the presence of the proteasome inhibitor PS-341 
(Figure 3.2B). 
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Figure 3.1  NSAIDs induce Bcl-XL degradation. 
Time course of Bcl-XL degradation.  HCT116 and BAX-KO cells were treated with 
500 μmol/L indomethacin.  Changes in Bcl-XL levels were analyzed by Western 
blotting at the indicated time points after indomethacin treatment. 
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Figure 3.2  NSAIDs induce proteasome-mediated Bcl-XL degradation. 
A, Effect of proteasome inhibitor PS-341 on Bcl-XL level.  HCT116 cells were 
treated with two sub-cytotoxic doses of PS-341.  Changes in Bcl-XL levels were 
analyzed by Western blotting at the indicated time points after treatment. 
B, Analysis of Bcl-XL degradation.  HCT116 cells were transiently co-transfected 
with HA-tagged ubiquitin and V5-tagged Bcl-XL plasmids for 12 hours.  After 
transfection, HCT116 cells were treated with 120 μmol/L sulindac alone or in 
combination with the proteasome inhibitor PS-341.  The appearance of poly-
ubiquitinated Bcl-XL at indicated time points was analyzed by immunoprecipitation 
(IP) with a V5 antibody. 
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3.2.2 NSAIDS DISRUPT INTERACTION BETWEEN BAX AND 
BCL-XL 
 
Treatment of HCT116 cells with NSAIDs caused proteasomal degradation of 
Bcl-XL; however the degradation of Bcl-XL appeared to be incomplete following a 24 
hour treatment with NSAIDs, which is sufficient in inducing the appearance of 
apoptotic markers such as chromatin condensation, nuclear fragmentation, and 
activation of caspases (data not shown).  The partial persistence of Bcl-XL in NSAID-
treated cells coincided with a stable level of BAX throughout the progression of 
apoptosis, suggesting that the apoptosis induced by sulindac and indomethacin was 
dependent on the continuous presence of functional BAX protein in colon cancer 
cells.  Since the remaining Bcl-XL could potentially neutralize the pro-apoptotic 
function of BAX through heterodimerization, the level of interaction between 
endogenous anti-apoptotic Bcl-XL and pro-apoptotic BAX proteins was analyzed 
during NSAID treatment.  HCT116 cells were treated with 500 μmol/L indomethacin 
for up to 16 hours, and whole cell lysates were collected.  Purification of endogenous 
BAX–Bcl-XL complexes by immunoprecipitating with anti-BAX antibody indicated a 
time-dependent reduction in BAX–Bcl-XL complexes in NSAID-treated cells (greater 
than 60% reduction by 16 hours of treatment as determined by densitometry analysis 
of protein band intensity on the developed film) (Figure 3.3).  These findings suggest 
that in addition to depletion of the Bcl-XL pool within the cell, the disruption of 
BAX–Bcl-XL interactions was important for initiating an NSAID-induced apoptotic 
response in colon cancer cells. 
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Figure 3.3  Dissociation of BAX and Bcl-XL during NSAID treatment. 
The association between endogenous BAX and Bcl-XL following treatment with 120 
μmol/L sulindac was analyzed at indicated time points by immunoprecipitation (IP) 
with anti-BAX antibody. 
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3.2.3 NSAIDS INDUCE BAX TRANSLOCATION FROM CYTOSOL 
TO MITOCHONDRIA 
 
Since BAX plays an important pro-apoptotic role at the mitochondrial 
membrane of cells that have been challenged with an apoptosis-inducing stimulus, the 
subcellular distribution of BAX was analyzed during NSAID treatment in HCT116 
cells.  Following the isolation of mitochondrial and cytosolic fractions, BAX was 
initially found to be localized in both fractions of untreated cells.  Sulindac-treated 
cells displayed a time-dependent accumulation of BAX in the mitochondrial fraction 
(greater than 40% increase by 32 hours of treatment as determined by densitometry 
analysis of protein band intensity on the developed film), which coincided with a 
reduction of BAX present in the cytosolic fraction (Figure 3.4), indicating that a 
translocation of BAX from the cytosolic pool to the mitochondrial pool may play a 
role in mediating the initiation of apoptotic cascade in cells treated with NSAIDs.  
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Figure 3.4  NSAIDs induce BAX accumulation in the mitochondria. 
Analysis of BAX localization during a time course of sulindac treatment.  Following 
treatment with 120 μmol/L sulindac, the mitochondrial and cytosolic fractions were 
isolated at indicated time points.  The expression of BAX was analyzed by Western 
blotting.  COX IV and α-tubulin, which are exclusively expressed in the mitochondria 
and cytosol, respectively, were used as controls for loading and fractionation. 
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3.2.4 MULTIMERIZATION AND TRANSMEMBRANE DOMAINS 
OF BAX ARE REQUIRED FOR NSAID-INDUCED 
APOPTOSIS 
 
To further elucidate the importance of dissociation of BAX from Bcl-XL and 
translocation of BAX to the mitochondria in NSAID-treated cells, the effects of 
NSAID treatment were studied in previously established BAX-KO cell lines with 
stable expression of various eGFP-BAX (eBAX) constructs (Figure 3.5A) [123].  The 
BAX gene encodes a protein that contains three BH domains (BH1-3) and a 
transmembrane domain (TM).  The domains and amino acid sequence that are 
required for its interactions with other Bcl-2 family proteins and for mitochondrial 
translocation were previously described [123].  The engineered BAX constructs 
contained a predicted defect in either the ability of BAX to interact with other BH3 
family proteins (eBAX-D1 and eBAX-M1), or the ability of BAX to localize to 
mitochondria (eBAX-D2 and eBAX-M3), corresponding to a mutation or deletion of 
the transmembrane (TM) domain (Figure 3.5A) [123].  Plasmids eBAX-D1 and eBAX-
M1 encoded full-length BAX proteins containing a deletion of the BH3 domain or a 
single-point mutation of the BH3 domain, respectively, with a predicted deficiency in 
protein-protein interactions.  Plasmids eBAX-D2 and eBAX-M3 encoded full-length 
BAX proteins containing a deletion of the TM domain or a point mutation of the TM 
domain, respectively (Figure 3.5A).  All constructs were experimentally verified by 
immunoprecipitation and immunostaining to exhibit the predicted loss of function 
[123].   
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Figure 3.5  BAX multimerization and mitochondrial localization domains are 
required for mediating NSAID-induced apoptosis. 
A, Previously, BAX-KO cells were stably transfected with BAX vectors containing 
deletions or mutations in multimerization or transmembrane domains [123]. 
B, BAX multimerization and mitochondrial localization domains are required for 
mediating NSAID-induced apoptosis.  Stable cell lines were treated with 120 μmol/L 
sulindac for 48 hours.  Apoptosis was analyzed by nuclear staining. 
C, Time course of caspase-3 activation.  Representative stable cell lines expressing 
wild-type or mutant BAX were treated with 120 μmol/L sulindac.  Caspase-3 
activation was analyzed by Western blotting at the indicated time points after sulindac 
treatment.  Arrow indicates active caspase-3 fragment. 
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BAX-KO cells with stable expression of eBAX constructs described above 
were treated with 120 μmol/L sulindac for 48 hours, at which point floating and 
attached cells were collected and analyzed for chromatin condensation and nuclear 
fragmentation to score apoptotic induction.  Apoptosis was significantly induced in 
cells expressing wildtype BAX (eBAX-wt), at a level similar to the parental HCT116 
cells (Figure 3.5B).  Expression of BAX constructs with a defective BH3 domain 
(eBAX-D1 and eBAX-M1) failed to rescue the resistance to NSAID-induced apoptosis 
in BAX-KO cells, while expression of BAX constructs with a defective TM domain 
resulted in an intermediate phenotype, characterized by an incomplete but significant 
resistance to apoptosis induced by NSAIDs (Figure 3.5B).  BAX-KO cells with stable 
expression of eBAX-wt and eBAX-D1 constructs were analyzed for caspase-3 
activation during treatment with 120 μmol/L sulindac for up to 48 hours.  Lack of 
NSAID-induced caspase-3 activation that was previously observed in BAX-KO cells 
was rescued by the expression of the eBAX-wt construct, but not by the eBAX-D1 
construct (Figure 3.5C).  Together, these results demonstrated the importance of the 
ability to form multimeric protein interactions mediated by the BH3 domain and to 
undergo mitochondrial localization mediated by the TM domain for BAX-mediated 
apoptotic response. 
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3.2.5 NSAIDS INDUCE MCL-1 EXPRESSION IN BAX-KO CELLS 
 
BAX-deficient HCT116 cells are resistant to apoptosis induced by a variety of 
different agents, including TRAIL and NSAIDs.  However, despite this block in 
apoptosis initiation upstream of mitochondria-driven changes, BAX-KO cells still 
display activation of caspase-8 and cleavage of Bid protein when treated with TRAIL 
or NSAIDs, suggesting a common pathway for the induction of apoptosis for these 
distinct agents.  Previously, the expression of the anti-apoptotic protein Mcl-1 has 
been shown to become upregulated in TRAIL-treated BAX-deficient HCT116 cells.  
Human Mcl-1 belongs to the Bcl-2 protein family of anti-apoptotic regulators and 
shares similar BH-multidomain structures as Bcl-2 and Bcl-XL [83].  It has been 
proposed that the increase in Mcl-1 expression likely confers additional protection 
against tBid in TRAIL-treated BAX-deficient cells [121].  Due to the similarity 
between TRAIL and NSAIDs in generating active tBid protein, the expression of 
several anti-apoptotic proteins, including Mcl-1 and members of the IAP family (data 
not shown), was analyzed in sulindac-treated HCT116 cells and BAX-KO cells.  The 
basal level of Mcl-1 protein was similar in untreated BAX-proficient and BAX-
deficient cells (Figure 3.6A).  However, unlike NSAID-sensitive HCT116 cells, 
NSAID-resistant BAX-KO cells showed significant increase in expression of Mcl-1 
and cIAP-1 (data not shown) proteins when treated with sulindac (Figure 3.6A).   
The upregulation of Mcl-1 expression in TRAIL-treated BAX-KO cells has 
been previously shown to depend on the activity of nuclear factor-kappa B (NF-κB) 
[121].  NF-κB is a transcription factor composed of two subunits, p50 and p65, which 
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can function independently or as a duo.  It is typically found in the cytoplasm in an 
inactive form bound to I-κB.  Phosphorylation of I-κB leads to its dissociation from 
NF-κB, followed by proteasomal degradation.  Uncoupling of I-κB and NF-κB 
induces activation of NFκB by allowing translocation into the nucleus where it 
promotes transcription.  We studied the activation of NF-κB signaling in NSAID-
treated cells by analyzing the phosphorylation of the NF-κB p65 subunit, 
phosphorylation of I-κB, an endogenous inhibitor of NF-κB, and NF-κB nuclear 
translocation.  A 24 hour treatment with sulindac induced a reduction of NF-κB 
phosphorylation and no change in I-κB phosphorylation in HCT116 and BAX-KO cell 
lines (Figure 3.6B).  Additionally, both cell lines indicated a minor increase in NF-κB 
nuclear levels following sulindac treatment (Figure 3.6C).  These results suggest that 
the apparent increase in Mcl-1 levels following sulindac treatment in BAX-KO cells 
occurred via an NF-κB–independent mechanism, since no difference between the 
levels of active NF-κB and inactive I-κB were observed between HCT116 cells, 
which did not show increased Mcl-1 expression, and BAX-KO cells. 
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Figure 3.6  Sulindac induces Mcl-1 expression in BAX-KO cells. 
A, Time course of Mcl-1 induction.  HCT116 and BAX-KO cells were treated with 
120 μmol/L sulindac.  Changes in Mcl-1 expression were analyzed by Western 
blotting at the indicated time points after sulindac treatment. 
B, Detection of NF-κB and I-κB phosphorylation.  Phospho-specific antibodies were 
used to study changes in activation of NF-κB and I-κB following sulindac treatment. 
C, Analysis of NF-κB localization.  HCT116 and BAX-KO cells were treated with 
120 μmol/L sulindac for 24 hours.  Cytosolic and nuclear fractions were isolated, and 
the expression of NF-κB was analyzed by Western blotting.  Lamin A/C, which is 
exclusively expressed in the nucleus, was used as controls for loading and 
fractionation. 
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3.2.6 ABLATION OF MCL-1 DOES NOT SENSITIZE BAX-KO 
CELLS TO NSAID-INDUCED APOPTOSIS 
 
Previously, reduction of Mcl-1 expression by c-Myc or the kinase inhibitor 
sorafenib was shown to sensitize BAX-KO cells to TRAIL-induced apoptosis [121].  
Since treatment with NSAIDs induced an upregulation of Mcl-1 in BAX-KO cells 
similar to TRAIL-treated cells, the significance of Mcl-1 expression in establishing 
resistance to NSAIDs in BAX-KO cells was analyzed.  Cells were transiently 
transfected with Mcl-1 siRNA before sulindac treatment.  Induction of Mcl-1 by 
sulindac was significantly blocked by Mcl-1 siRNA (Figure 3.7A).  However, in 
contrast to apoptosis induced by TRAIL, ablation of Mcl-1 expression failed to 
restore sensitivity to NSAID-induced apoptosis in BAX-KO cells (Figure 3.7B).  
Inhibition of NF-κB expression by siRNA transfection similarly had no effect on 
apoptosis induced by sulindac (Figure 3.7B).  These results indicate that Mcl-1 
induction is not responsible for imparting an additional level of resistance to 
apoptosis induced by NSAIDs, while the mechanism of NSAID-induced apoptosis 
appears to be independent of gene transcription regulated by NF-κB transcription 
factor in HCT116 colon cancer cells.  
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Figure 3.7  Mcl-1 induction is not necessary for resistance to NSAID-induced 
apoptosis in BAX-KO cells. 
A, Inhibition of Mcl-1 by siRNA knockdown.  BAX-KO cells were transiently 
transfected with indicated siRNA for 12 hours followed by 120 μmol/L sulindac 
treatment.  Mcl-1 expression was probed by Western blotting 48 hours after 
treatment.  Ctrl, control scrambled siRNA. 
B, Effects of Mcl-1 ablation on sulindac-induced apoptosis.  BAX-KO cells were 
transiently transfected with indicated siRNA for 12 hours followed by 200 μmol/L 
sulindac treatment.  Apoptosis induction was analyzed by Annexin V/PI staining.  
The percentage of apoptosis represents Annexin V/PI double-positive population.  
Ctrl, control scrambled siRNA.   
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3.3 DISCUSSION 
 
The induction of apoptosis by NSAIDs in human cancer cell lines has been 
well characterized.  However, the exact mechanisms underlying the anticancerous 
effects of NSAIDs remain unclear.  The initial role of NSAID-mediated inhibition of 
cyclooxygenase enzymes failed to provide a definitive answer, since the effects of 
NSAIDs have been shown to be equally potent in cell lines that expressed COX 
enzymes and those that did not.  In addition to COX-2 inhibition, recent evidence has 
indicated that NSAIDs-mediated anti-neoplastic effects are exerted through the 
activation of an apoptotic pathway [62].  This process involves activation and 
translocation of several key molecules and ultimately results in caspase activation in 
the malignant tissues.  Several novel COX-independent mechanisms for NSAIDs 
have been described that involve inhibition of NF-κB activation and downregulation 
of the anti-apoptotic protein Bcl-XL [124].  The present study aimed at elucidating the 
importance of several key apoptotic players, and their role in NSAID-induced 
apoptosis.  We analyzed the role of BAX and Bcl-XL, two functionally opposing 
members of Bcl-2 family of apoptotic regulators, in mediating the response of cancer 
cells to NSAIDs.  The availability of NSAID sensitive and isogenic NSAID resistant 
cell lines allowed the investigation of molecular events that followed the induction of 
apoptosis in sensitive cells and resistance to apoptosis in resistant cells. 
Initially, the reduction of Bcl-XL protein level was observed in HCT116 cells 
with wild-type BAX, an effect that was previously described [71].  Under similar 
treatment, there was no noticeable decrease in Bcl-XL in BAX-deficient HCT116 
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cells.  Since BAX-KO cells showed remarkable resistance to apoptosis induced by 
NSAIDs, which coincided with a lack of Bcl-XL degradation, the active degradation 
of Bcl-XL was proposed to act as a prerequisite for apoptosis initiation.  It was 
enticing to hypothesize that the degradation of anti-apoptotic Bcl-XL during early 
stages of apoptosis served as a possible mechanism by which cells generate a pool of 
active BAX protein by liberating BAX from the inhibitory interaction with Bcl-XL.  
Inhibition of cellular ubiquitin-proteasome machinery, which serves as a major 
pathway that regulates protein degradation and turn-over, indicated that Bcl-XL was 
indeed poly-ubiquitinated and degraded by the proteasome during NSAID treatment. 
The dissociation of BAX and Bcl-XL by NSAIDs presumably activates the 
pro-apoptotic function of BAX by promoting its mitochondrial translocation and 
multimerization.  The interaction between BAX and Bcl-XL was markedly inhibited 
by 16 hours of NSAID treatment.  At the same time, there was a noticeable 
accumulation of BAX in the mitochondria with concomitant reduction of BAX levels 
in the cytosol of NSAID-treated cells, favoring the model of the pro-apoptotic action 
of BAX at the mitochondria.  A recent study has indicated that NSAIDs celecoxib 
and indomethacin can induce a significant increase in the expression of PUMA, both 
at the RNA and protein levels, in AGS and Kato III human stomach carcinoma cell 
lines [125].  PUMA is a member of the BH3-only group of Bcl-2 family of apoptotic 
regulator proteins, while also being a downstream target of the p53-mediated 
transcriptional activity.  The increase in PUMA levels by NSAIDs occurred through a 
COX-independent mechanism and coincided temporally with the dissociation 
between BAX and Bcl-XL observed in the present study, taking place between 12 and 
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24 hours of NSAID treatment.  Additionally, PUMA has been demonstrated to 
mediate the disruption of BAX–Bcl-XL complexes by actively competing with BAX 
for binding to Bcl-XL [123].  Such an effect of PUMA was dependent on the BH3 
domain, since PUMA containing a deletion of the BH3 domain was unable to 
dissociate BAX and Bcl-XL [123].  Taken together, the presently observed 
dissociation of BAX from Bcl-XL during NSAID treatment, combined with the 
previously published data outlining the NSAID-induced upregulation of PUMA and 
the role of PUMA in disrupting the interaction between BAX and Bcl-XL, suggest a 
possible mechanism by which NSAIDs promote apoptosis: upregulation of PUMA 
expression by NSAIDs in turn promotes BAX-mediated release of mitochondrial 
apoptogenic factors through competitive binding to Bcl-XL. 
The findings illustrated above are based on experiments performed in BAX-
proficient cells undergoing NSAID-induced apoptosis, suggesting that the induction 
of cell death occurs as a result of displacement of BAX from Bcl-XL.  Previously 
established stable cell lines expressing BAX mutants that are unable to form 
multimers (eBAX-D1 and eBAX-M1) did not undergo NSAID-induced apoptosis, 
suggesting that the ability of BAX to form protein-protein complexes is critical for its 
function in NSAID-induced apoptosis.  Stable cell lines expressing BAX mutants in 
the TM domain (eBAX-D2 and eBAX-M3), which disrupt its mitochondrial 
localization, were resistant to NSAID-induced apoptosis, suggesting that the 
mitochondrial localization of BAX plays an important role in mediating its pro-
apoptotic function.  NSAID-induced caspase activation also appeared to be dependent 
on these BAX-related changes, as illustrated by a representative cell line with a 
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multimerization-defective BAX mutant.  Together, these results support the model in 
which the multimerization of BAX at the mitochondrial outer membrane facilitates 
the initiation of the apoptotic response in cells treated with NSAIDs.   
The role of another anti-apoptotic member of Bcl-2 family of apoptotic 
regulators, Mcl-1, has been recently explored in TRAIL-induced apoptosis in BAX-
proficient and BAX-deficient HCT116 cells [121].  Despite being resistant to 
apoptosis induced by TRAIL, BAX-KO cells seemingly developed an additional 
strategy of inhibiting the apoptotic machinery by inducing the expression of Mcl-1, 
which acts similar to Bcl-XL by interacting with pro-apoptotic BH3-only proteins and 
sequestering their activity.  A recent study has indicated a similarity between the 
engagement of the death receptor pathway by TRAIL and sulindac.  While treatment 
of BAX-KO cells with sulindac resulted in a similar induction of Mcl-1, inhibition of 
Mcl-1 expression failed to sensitize BAX-KO cells to apoptosis induced by NSAIDs, 
as opposed to restoration to TRAIL-mediated apoptosis [121]. 
In summary, these results demonstrated that NSAIDs induce apoptosis by 
inducing proteasome-mediated degradation of Bcl-XL and displacing BAX from Bcl-
XL, thereby promoting BAX multimerization and mitochondrial translocation. 
 52
3.4 CONCLUSION 
 
In this study, we investigated the mechanisms by which nonsteroidal anti-
inflammatory drugs (NSADs) modulate the intrinsic pathway of apoptosis.  We 
focused on analyzing the events upstream of mitochondria and studied the roles of 
Bcl-2 family members BAX, Bcl-XL and Mcl-1 in mediating an apoptotic response in 
human colon cancer cells treated with sulindac and indomethacin, two members of 
the NSAID family.  Previously observed degradation of Bcl-XL in NSAID-treated 
cells was shown to depend on the ubiquitin-proteasome pathway that serves as a 
common mechanism of protein turn-over.  Treatment with the small molecule 
proteasomal inhibitor PS-341 induced a time-dependent accumulation of Bcl-XL in 
untreated cells, while treatment with NSAIDs combined with PS-341 resulted in 
accumulation of ubiquitin-conjugated Bcl-XL species.  Degradation of Bcl-XL 
coincided with dissociation of BAX–Bcl-XL complexes and translocation of BAX 
from the cytosol to the mitochondria of NSAID-treated cells, in agreement with a 
previously suggested role for BAX in mediating the pore-forming function at the 
mitochondria during initiation of apoptosis.  Analysis of Mcl-1 expression indicated a 
time-dependent induction in Mcl-1 levels in BAX-deficient cells following treatment 
with NSAIDs; the induction of Mcl-1 was not observed in wild-type HCT116 cells.  
Inhibition of Mcl-1 expression using RNA interference failed to sensitize BAX-KO 
cells to NSAID-induced apoptosis, suggesting the involvement of different pathways 
of apoptosis regulation in NSAID-treated cells and TRAIL-treated cells. 
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4 THE ROLE OF SMAC IN MEDIATING NSAID-INDUCED 
APOPTOSIS 
 
4.1 INTRODUCTION 
 
Prevention of human cancers through the use of chemical agents or dietary 
manipulation has emerged as a promising approach to reduce morbidity and mortality 
of cancer [14].  A number of epidemiologic studies, clinical trials, and animal studies 
have shown that nonsteroidal anti-inflammatory drugs (NSAID), such as sulindac and 
aspirin, are effective against colorectal cancer, the second leading cause of cancer-
related death [105, 106].  However, the mechanisms underlying the anti-neoplastic 
effects of NSAIDs remain unclear.  The effects of NSAIDs are incomplete, and 
resistance to NSAIDs is often developed [105, 106].  Furthermore, the side effects 
associated with high dose of NSAIDs, such as the cardiovascular toxicity of the 
cyclooxygenase 2 (COX-2)–specific inhibitors, have presented a significant obstacle 
for general use of these agents for cancer prevention [126]. 
Among many described activities of NSAIDs, induction of apoptosis 
secondary to inhibition of COX enzymes seems to play a critical role in NSAID-
mediated chemoprevention [105-107].  Apoptosis is a major mechanism regulating 
turnover of intestinal epithelial cells from which colon tumors are derived [108].  
During the formation of a colon tumor, apoptosis is progressively inhibited due to 
oncogenic mutations [109].  Deregulation of apoptosis is necessary for oncogenic 
transformation and drives neoplastic cells to gain additional tumorigenic features 
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[110].  NSAIDs have been found to induce apoptosis in colon cancer cells in vitro and 
in vivo [105, 106].  The apoptotic level can be used as a biomarker for NSAID-
mediated chemoprevention [72, 111].  Furthermore, it has been shown that NSAID 
treatment can reverse the anti-apoptotic effects of COX-2 [63]. 
In mammalian cells, apoptotic cell death is executed through a cascade of 
events, among which a key event is the translocation of apoptogenic proteins from the 
mitochondria into the cytosol to trigger caspase activation.  Cytochrome c is released 
from the mitochondria into the cytosol, where it binds to other proteins to form an 
‘apoptosome’ multi-protein complex [101].  SMAC is the second mitochondrial 
protein found to be released into the cytosol during apoptosis [88] [127].  Under non-
apoptotic cellular conditions, the BIR-2 and BIR-3 domains of IAPs participate in an 
inhibitory interaction with initiator caspases, including caspase-3, and executioner 
caspases, including caspase-9, respectively (Figure 4.1) [79, 128, 129].  After its 
release, SMAC binds to the BIR-2 and BIR-3 domains of IAPs through its N-terminal 
AVPI domain and relieves their inhibition of caspases (Figure 4.1) [129]. 
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Figure 4.1  Role of SMAC in promoting apoptosis. 
Activation of caspases is inhibited by interaction with IAPs.  Cytosolic SMAC 
promotes caspase activation by releasing caspases from IAPs, leading to apoptosis. 
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Previous studies showed that SMAC plays an essential role in NSAID-
induced apoptosis in colon cancer cells [99].  SMAC is consistently released from the 
mitochondria into the cytosol during NSAID-induced apoptosis.  Deletion of SMAC 
by homologous recombination or knockdown of SMAC by RNA interference 
abrogates NSAID-induced caspase activation and apoptosis [99].  Unexpectedly, 
NSAID-induced cytochrome c release was also found to be compromised in the 
SMAC-deficient cells [99].  This finding suggested that SMAC had the potential to 
influence the release of cytochrome c (Figure 4.2), a surprising effect that could not 
be deduced from the canonical pathway detailing the release of mitochondrial 
apoptogenic factors, such as SMAC and cytochrome c, occurring as independent 
events.  In this study, we further investigated how SMAC functions in NSAID-
induced apoptosis. 
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Figure 4.2  Proposed role of SMAC in regulating caspase activation and 
cytochrome c release through a feed-back mechanism. 
Based on previous observations that SMAC deficiency inhibits cytochrome c release 
during NSAID treatment, a feed-back mechanism was proposed through which 
release of SMAC into the cytosol leads to release of cytochrome c by promoting 
activation of caspase cascade. 
 
 
Cytosol 
BAX Bcl-XL 
Cytochrome c 
Caspase-9 
IAP Caspase-3 
Cellular targets 
Mitochondria 
Bcl l-XL 
SMAC 
Apoptosis 
 58
4.2 RESULTS 
 
4.2.1 NSAID-INDUCED RELEASE OF CYTOCHROME C IS 
DELAYED AND ATTENUATED IN SMAC-KO CELLS 
 
Previously, SMAC deficiency was shown to perturb NSAID-induced release 
of cytochrome c and apoptosis-inducing factor in HCT116 colon cancer cells [99].  
To further characterize how SMAC mediates NSAID-induced apoptosis, the time 
courses of apoptotic events were analyzed in HCT116 cells treated with sulindac at 
120 μmol/L, which is the minimum concentration that is necessary to induce a high 
level (>70%) of apoptosis in these cells [99].  A burst of SMAC release was detected 
as early as 8 hours after the treatment (Figure 4.3A), long before cells started to show 
morphologic signs of apoptosis.  Caspase-3 was dissociated from IAP family 
members cIAP-1 and cIAP-2 as early as 8 hours after sulindac treatment (Figure 
4.3B).  At 12 to 16 hours, caspase-3 was found to be activated (Figure 4.3C), but only 
a very low level (<5%) of nuclear fragmentation could be detected (data not shown).   
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Figure 4.3  SMAC release and caspase-3 activation in NSAID-treated cells. 
A, Time course of SMAC release.  HCT116 cells were treated with 120 μmol/L 
sulindac.  Cytosolic fractions at the indicated time points were isolated, and the 
expression of SMAC was analyzed by Western blotting.  COX IV and α-tubulin, 
which are exclusively expressed in the mitochondria and cytosol, respectively, were 
used as controls for loading and fractionation. 
B, After HCT116 cells were treated with 120 μmol/L sulindac, the association 
between caspase-3 and cIAP-1 or cIAP-2 at indicated time points was analyzed by 
immunoprecipitation (IP) with cIAP-1 or cIAP-2 antibodies, respectively. 
C, Time course of caspase-3 activation.  Caspase-3 activation was analyzed by 
Western blotting at the indicated time points after sulindac treatment.  Arrows 
indicate caspase-3 cleavage fragments. 
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In contrast, the majority of cytochrome c release occurred at 24 and 32 hours 
after the treatment (Figure 4.4) when high levels (>50%) of nuclear fragmentation 
could be detected, bolstering the notion that the initial and brief release of SMAC was 
sufficient to manifest its role in promoting the initiation of apoptosis, while the 
continued, steady release of cytochrome c ensured the successful progression of an 
apoptosis program in NSAID-treated cells [71, 99].  However, sulindac-induced 
cytochrome c release and nuclear fragmentation were significantly delayed and 
attenuated in the SMAC-KO cells compared with the parental HCT116 cells (Figure 
4.4 and data not shown) [99].  These results showed that SMAC release and 
cytochrome c-independent caspase-3 activation are early events in NSAID-induced 
apoptosis and regulate later apoptotic events, such as cytochrome c release and 
nuclear fragmentation. 
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Figure 4.4  Cytochrome c release in HCT116 and SMAC-KO cells. 
Cytochrome c release in HCT116 and SMAC-KO cells treated with 120 μmol/L 
sulindac was analyzed by Western blotting.  COX IV and α-tubulin, which are 
exclusively expressed in the mitochondria and cytosol, respectively, were used as 
controls for loading and fractionation. 
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4.2.2 IAP BINDING IS REQUIRED FOR SMAC-MEDIATED 
CASPASE-3 ACTIVATION AND CYTOCHROME C RELEASE 
 
To further study how SMAC mediates cytochrome c release, we tested 
whether the IAP inhibition and/or caspase-3 activation functions of SMAC, which are 
mediated by the N-terminal AVPI domain of cytosolic SMAC [130], are necessary 
for NSAID-induced apoptosis and cytochrome c release.  The co-crystal structure of 
SMAC in complex with the XIAP BIR3 domain shows the SMAC N-terminus 
interacts with a groove formed on the BIR3 surface [131].  The four SMAC residues 
(AVPI) that contact BIR3 domain do so by docking a fourth strand onto an existent 
three-stranded antiparallel ß sheet [131].  This AVPI domain of SMAC has been 
demonstrated to be important and sufficient for mediating the pro-apoptotic role of 
SMAC in mediating a cellular apoptosis response [130, 132].  Wild-type (AVPI) or 
mutant SMAC containing a deletion of alanine in the AVPI domain (ΔA), which 
abolishes the interactions between SMAC and IAPs [130], were transfected into the 
SMAC-KO cells (Figure 4.5A).  Following selection with Geneticin (G418), two 
independent stable cell lines expressing the wild-type or mutant SMAC were selected 
and analyzed for their responses to 120 μmol/L sulindac. 
The deficiency in NSAID-induced apoptosis in the SMAC-KO cells was 
completely rescued by the expression of the wild-type, but not the mutant, SMAC 
(Figure 4.5B).  Since the activation of the caspase cascade serves as a hallmark of 
apoptotic cell death, we analyzed the activation of caspase-3 in HCT116, SMAC-KO 
and established stable cell lines.  In agreement with their resistance to NSAID-
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induced apoptosis, SMAC-KO cells showed a strong attenuation of caspase-3 
activation (Figure 4.6A).  Expression of the wild-type SMAC rescued caspase-3 
activation in the SMAC-KO cells (Figure 4.6A). 
Importantly, wild-type, but not the mutant, SMAC restored sulindac-induced 
cytochrome c release to a level similar to that in the parental HCT116 cells (Figure 
4.6B).  These results suggest that inhibition of IAPs by cytosolic SMAC through their 
direct interactions promotes cytochrome c–independent caspase-3 activation at early 
stage and cytochrome c release at later stages in NSAID-induced apoptosis. 
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Figure 4.5  The IAP interacting function of SMAC is necessary for its activity in 
NSAID-induced apoptosis. 
A, SMAC-KO cells were transfected with wild-type (AVPI) or mutant SMAC 
containing a deletion of alanine in the AVPI domain (ΔA).  Two pairs of clones with 
stable expression of each SMAC construct were isolated, and SMAC expression was 
verified by Western blotting. 
B, The indicated cell lines were treated with 120 μmol/L sulindac for 48 hours.  
Apoptosis was analyzed by nuclear staining. 
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Figure 4.6  The IAP interacting function of SMAC is necessary for its activity in 
NSAID-induced caspase activation and cytochrome c release. 
A, Effects of wild-type and mutant SMAC on NSAID-induced caspase activation 
were analyzed by Western blotting.  Arrows indicate caspase-3 cleavage fragments. 
B, Effects of wild-type and mutant SMAC on NSAID-induced cytochrome c release.  
HCT116, SMAC-KO, and SMAC-KO cells with stable expression of wild-type SMAC 
(AVPI) or mutant SMAC (ΔA) were treated with 120 μmol/L sulindac.  Cytochrome 
c release was analyzed by Western blotting.  COX IV and α-tubulin, which are 
exclusively expressed in the mitochondria and cytosol, respectively, were used as 
controls for loading and fractionation. 
 
 
 66
4.2.3 CASPASE-3 ACTIVATION IS NECESSARY FOR SMAC-
MEDIATED CYTOCHROME C RELEASE 
 
 
Next, we determined whether caspase-3 activation is critical for NSAID-
induced and SMAC-mediated apoptosis and cytochrome c release, since activation of 
caspase-3 occurs downstream of SMAC release from the mitochondria into the 
cytosol.  Cells were transiently transfected with two non-overlapping caspase-3 
siRNA constructs (Cas-3 986 and Cas-3 182) before sulindac treatment.  Both 
caspase-3 siRNA constructs displayed a comparable efficacy in down-regulating 
caspase-3 expression (Figure 4.7A).  Knockdown of caspase-3 expression resulted in 
a significant reduction of sulindac-induced apoptosis in HCT116 cells (Figure 4.7B).  
However, no further decrease in apoptosis was observed after knockdown of caspase-
3 in the SMAC-KO cells (Figure 4.7B), suggesting that SMAC and caspase-3 function 
in a linear pathway to promote NSAID-induced apoptosis.  Caspase-3 knockdown 
also led to significant inhibition of cytochrome c release (Figure 4.8).  The critical 
role of caspase-3 in promoting sulindac-induced cytochrome c release was confirmed 
by treating HCT116 and another colon cancer cell line HT29 using the caspase-3 
inhibitor Z-DEVD-fmk (Figure 4.8). 
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Figure 4.7  Caspase-3 is necessary for NSAID-induced apoptosis. 
A, Inhibition of caspase-3 by siRNA knockdown.  Caspase-3 expression was probed 
by Western blotting 24 hours after HCT116 cells were transiently transfected with 
indicated siRNA.  Ctrl, control scrambled siRNA. 
B, Effects of caspase-3 knockdown on sulindac-induced apoptosis.  Parental and 
SMAC-KO HCT116 cells were transfected with caspase-3 or control siRNA for 24 
hours followed by sulindac (120 μmol/L) treatment.  Apoptosis was analyzed by 
nuclear staining 48 hours after sulindac treatment. 
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Figure 4.8  Caspase-3 is necessary for NSAID-induced cytochrome c release. 
Effects of caspase-3 inhibition on NSAID-induced cytochrome c release.  HCT116 
and HT29 cells were transfected with control scrambled or caspase-3 siRNA or 
treated with caspase-3 inhibitor Z-DEVD-fmk for 24 hours followed by sulindac (120 
μmol/L for HCT116; 180 μmol/L for HT29) treatment.  Cytochrome c release 24 
hours after the treatment was analyzed.  COX IV and α-tubulin, which are exclusively 
expressed in the mitochondria and cytosol, respectively, were used as controls for 
loading and fractionation. 
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4.2.4 ROLE OF BID AND BIM IN MEDIATING APOPTOSIS 
INDUCED BY NSAIDS 
 
The dependence of mitochondrial cytochrome c release on the cytosolic 
actions of SMAC and caspase-3 suggested a protein, presumably a caspase or a 
caspase substrate, could translocate from the cytosol to the mitochondria to induce 
cytochrome c release (Figure 4.2).  Initially, the direct involvement of caspase-3 itself 
was considered, based on reports of caspase-3 mitochondrial accumulation under 
specific apoptotic conditions.  However, no mitochondrial accumulation of caspase-3 
could be detected after sulindac treatment (data not shown).  Another candidate was 
the BH3-only Bcl-2 family member Bid, which is cleaved by caspases in the 
cytoplasm [133].  In considering the role of Bid in mediating the caspase-3–
dependent regulation of cytochrome c release, the processing to its active, truncated 
form and its sub-cellular localization were analyzed in wild-type HCT116 cells, as 
well as BAX-KO cells that are highly resistant to NSAID-induced apoptosis and 
SMAC-KO cells that show an intermediate level of resistance to NSAID-induced 
apoptosis.  The truncated tBid can translocate to the mitochondria to induce 
cytochrome c release, presumably by directly interacting with BAX and Bak through 
its BH3 domain and inducing oligomerization of BAX and Bak [133].   
It was found that Bid was indeed cleaved, and tBid was enriched in the 
mitochondria after sulindac treatment (Figure 4.9).  However, the cleavage and 
translocation of Bid were also detected at the same level in the BAX-KO and SMAC-
KO cells (Figure 4.9), which are deficient in NSAID-induced apoptosis and 
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cytochrome c release, excluding Bid as the candidate for regulating SMAC-mediated 
cytochrome c release [71, 99].  Bim, another BH3-only protein and a caspase 
substrate that can translocate to the mitochondria, underwent similar proteolytic 
cleavage (Figure 4.9) [134].  Although the shorter forms of Bim were enriched in the 
mitochondria of sulindac-treated HCT116 cells, no difference was observed in the 
BAX-KO and SMAC-KO cells (Figure 4.9).  The apparent lack of differential 
processing and subcellular localization of Bid and Bim in NSAID-sensitive HCT116 
versus NSAID-resistant BAX-KO and SMAC-KO cells led us to conclude that these 
effects were occurring by an unrelated mechanism.  Therefore, Bid and Bim did not 
seem to play a role in NSAID-induced and SMAC-mediated cytochrome c release. 
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Figure 4.9  Bid and Bim do not mediate feed-back mechanism. 
Expression of Bid and Bim in sulindac-treated cells.  After treatment of HCT116, 
BAX-KO and SMAC-KO cells with 120 μmol/L sulindac for 24 hours, the cytosolic 
and mitochondrial fractions were analyzed for Bid and Bim expression by Western 
blotting.  Arrows indicate Bid and Bim cleavage fragments.  COX IV and α-tubulin, 
which are exclusively expressed in the mitochondria and cytosol, respectively, were 
used as controls for loading and fractionation. 
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4.2.5 ANALYSIS OF PROPOSED FEED-BACK MECHANISM 
DURING NSAID-INDUCED APOPTOSIS BY TWO-
DIMENSIONAL GEL ELECTROPHORESIS 
 
An unbiased proteomics approach was next considered as an appropriate 
method to identify a suitable candidate that could translate NSAID-induced activation 
of the caspase cascade into the release of cytochrome c.  Mitochondrial fractions, 
obtained from sulindac-treated HCT116 and BAX-KO cells, were analyzed using 2-D 
gel electrophoresis followed by silver staining to identify unique protein species that 
underwent mitochondrial translocation exclusively in NSAID-sensitive cells.  The 
initial attempt at 2-dimensional resolution of mitochondrial proteins indicated an 
abundance of high molecular weight species (vertical direction) that presumably 
represented the respiratory complexes responsible for mitochondrial energy 
generation (Figure 4.10).  The dominant ‘heavy’ proteins had a negative effect on the 
proper isoelectric focusing (horizontal direction) and distribution of the less abundant 
‘light’ proteins, which represented a suitable location for the proposed candidate 
molecule, resulting in a suboptimal protein visualization.  To address this concern, 
mitochondrial fractions obtained from similarly treated HCT116 and BAX-KO cells 
were loaded onto centrifugal filter columns containing a size-exclusion membrane 
with 100kDa nominal molecular weight limit in order to trap and remove the 
abundant high molecular weight proteins while enriching the low molecular weight 
proteins.  The resulting eluates were similarly analyzed using a 2-D SDS-PAGE gel.  
However, this strategy resulted in an overall reduction of both high and low 
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molecular weight populations and thus proved unsuccessful in improving the 
detection of ‘light’ proteins (Figure 4.10).  While several candidate ‘hits’ were 
observed that were uniquely present in sulindac-treated mitochondria obtained from 
HCT116 cells and absent in BAX-KO cells (Figure 4.10), their identities have not 
been analyzed by mass spectrometry.  These findings require further validation in 
additional colon cancer cell lines and with another member of NSAID family of 
drugs. 
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Figure 4.10  Analysis of protein population in sulindac-treated cells. 
After treatment of HCT116 and BAX-KO cells with 120 μmol/L sulindac for 24 
hours, the mitochondrial fractions were isolated and analyzed by 2-D SDS-PAGE.  
The gels were fixed and visualized by Silver stain.  Top, analysis of entire 
mitochondrial proteome from sulindac-treated cells; bottom, analysis of 
mitochondrial proteins following purification through a 100 kDa size exclusion 
filtration column.  Arrows indicate protein species unique to HCT116 cells. 
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4.3 DISCUSSION 
 
In this study, it was found that SMAC release and cytochrome c release 
proceed through different time courses during NSAID-induced apoptosis, with the 
bulk of SMAC release occurring much earlier compared with that of cytochrome c 
release.  The majority of cytochrome c release was abolished in the SMAC-KO cells, 
suggesting that SMAC plays an important role in promoting cytochrome c release and 
full execution of NSAID-induced apoptosis.  Studies by other groups also showed 
that the release of different mitochondrial apoptogenic proteins is coordinated and 
occurs through different time courses [135].  The IAP-interacting activity of SMAC, 
which is mediated by the N-terminal AVPI domain, is critical for its ability to 
promote caspase activation and cytochrome c release during NSAID-induced 
apoptosis.  Because IAP inhibition occurs in the cytoplasm whereas cytochrome c is 
located in the mitochondria before its release, a feed-back loop involving protein 
translocation seems to drive the events leading to cytochrome c release.  A similar 
function of SMAC in DNA damage-induced apoptosis mediated by the BH3-only 
protein PUMA was recently described [136].  However, the requirement of SMAC 
for full execution of apoptosis does not seem to be general, as only few classes of 
agents among a number of stimuli tested, including NSAIDs, PUMA, and TRAIL, 
were found to be dependent on SMAC to induce apoptosis [99].  Under different 
conditions, it is possible that cytochrome c plays a major role in driving this feed-
back amplification loop [137]. 
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Using siRNA and inhibitor approaches, the activation of capspase-3 was 
shown to be a critical event in this feed-back loop.  Several previous studies have also 
shown the functions of other caspases, including caspase-2 and caspase-7, in 
promoting mitochondrial events during apoptosis [138-140].  However, the link 
between caspase-3 activation and cytochrome c release remains to be identified.  We 
did not detect any mitochondrial accumulation of caspase-3 in HCT116 cells 
undergoing sulindac-induced apoptosis (data not shown), excluding the possibility 
that caspase-3 itself directly induces cytochrome c release.  Analysis of pro-apoptotic 
caspase substrates ruled out the BH3-only proteins Bid and Bim as potential 
candidates, because their cleavage and translocation were intact in the BAX-KO and 
SMAC-KO cells that are deficient in NSAID-induced apoptosis.  Several other 
proteins that can translocate from the cytosol to the mitochondria and promote 
cytochrome c release remain to be examined.  It is also possible that more than one 
protein mediate the intermediate steps between caspase-3 activation and cytochrome c 
release.  To identify the mediators of this feed-back loop, it might be useful to 
compare the mitochondrial components in the wild-type and BAX-KO cells using an 
unbiased proteomic approach.  While an initial look at the distribution of 
mitochondrial proteins in wild-type and BAX-KO cells indicated some unique ‘hits’ 
present in sulindac-treated wild-type cells, these candidates must withstand rigorous 
validation before any molecular biology experiments can be considered. 
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4.4 CONCLUSION 
 
In this study, we investigated the mechanisms behind the pro-apoptotic 
activity of NSAIDs by analyzing the molecular events that take place following the 
disruption of mitochondrial membrane integrity and the subsequent release of 
mitochondrial apoptogenic factors.  The release of SMAC into the cytosol preceded 
the appearance of morphological characteristics of apoptosis and coincided with 
release of caspases from inhibitor caspase-IAP complexes.  The disruption of 
caspase-IAP interactions occurred shortly before the appearance of caspase-3 
processing, in agreement with the predicted, chronologically accurate sequence of 
molecular events during apoptosis initiation.  While the release of SMAC occurred as 
a brief burst, the release of cytochrome c was time-dependent, and the cytosolic 
accumulation of cytochrome c continued to steadily increase with NSAID treatment.   
Previously characterized resistance of SMAC-deficient HCT116 cells to NSAID-
induced apoptosis was recapitulated in delayed and largely attenuated release of 
cytochrome c in these cells, suggesting an existence of a feed-back mechanism by 
which release of SMAC coordinated the release of cytochrome c in NSAID-treated 
cells.  The apoptosis-mediating function of SMAC during NSAID treatment involved 
a functional IAP binding domain, as cells stably expressing mutant SMAC failed to 
rescue the resistant phenotype of SMAC-KO cells, as characterized by caspase 
activation and release of cytochrome c.  Analysis of the proposed feed-back 
mechanism regulating cytochrome c release indicated the crucial role of caspase-3, as 
inhibition of caspase-3 activity by z-DEVD-fmk or reduction of caspase-3 expression 
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by RNA interference significantly blocked NSAID-induced release of cytochrome c 
in multiple cell lines.  The search for molecular mediators of caspase-dependent 
cytochrome c release ruled out Bid and Bim, as their activation and mitochondrial 
translocation was unaffected in NSAID-resistant BAX-KO and SMAC-KO cells. 
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5 EFFECT OF SMAC MIMETICS ON NSAID-INDUCED 
APOPTOSIS 
 
5.1 INTRODUCTION 
 
 Defects in apoptosis initiation or execution mechanisms caused by 
deregulated expression and/or function of anti-apoptotic or pro-apoptotic molecules 
are likely to contribute to tumor progression and resistance to antitumor therapies, 
including chemotherapy, ionizing irradiation, and immunotherapy [141].  The 
unfolding of the complex pathways involved in apoptosis signaling has stimulated 
intensive efforts to restore apoptosis in cancer cells for therapeutic purposes [142].   
Inhibitor of apoptosis proteins (IAPs) inhibit the protease activity of caspases by 
forming direct interactions with caspases via the characteristic 70-residue zinc-
containing domain termed the baculovirus inhibitory repeat (BIR) [131].  XIAP was 
shown to interact with initiator caspase-9 and executioner caspase-3 and -7 through its 
BIR3 and BIR2 domains, respectively [101]. 
It has been shown that SMAC overexpression and treatment with SMAC 
mimetic peptides can bypass mitochondrial regulation and enhance the pro-apoptotic 
effects of several anticancer agents, such as tumor necrosis factor (TNF)–related 
apoptosis-inducing ligand (TRAIL) [88, 143-146].  Structural analysis has shown that 
the four N-terminal Ala-Val-Pro-Ile (AVPI) amino acids of SMAC mediate the 
recognition of a surface groove on the BIR3 domain of XIAP and play an essential 
role during binding of SMAC to members of the IAP family.  SMAC peptides based 
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on the N-terminal AVPI domain have been previously reported to enhance caspase-3 
activation in a cell-free system and sensitize tumor cells to pro-apoptotic stimuli both 
in vitro and in vivo [129, 144].  
Several small molecules mimicking the AVPI domain of SMAC have also 
been developed [131, 147, 148].  For example, a compound called C3 was 
synthesized based on the structure of SMAC [131].  C3 is a symmetric dimer of an 
oxazoline-derived compound that can penetrate cell membranes and bind to the IAPs 
with an affinity equal to that of SMAC.  The active compound, C3, differs from the 
inactive, control compound, C4, by substitutions at two sites [131].  The dimer form 
representing the C3 compound displayed a greater activity in neutralizing endogenous 
IAP activity in HeLa cell extract than the monomer form [131].  This observation 
may be attributable to bivalent interaction with adjacent BIR domains in XIAP [131].  
Recent evidence suggests that SMAC, a native homodimer, binds XIAP in a similar 
fashion [149]. 
Nanomolar concentrations of C3 promote both TRAIL-induced and TNF-α–
induced apoptosis in human cancer cells [131].  However, it remains unclear how 
SMAC mimetics potentiate apoptosis induced by anticancer agents.  SMAC release 
occurs after mitochondrial outer membrane permeabilization, a process thought to 
happen after commitment to cell death [150]. 
Although numerous efforts have been made toward developing therapeutic 
agents, manipulation of apoptotic pathways for chemoprevention has not been 
extensively explored.  In this study, we investigated the effects of small molecule 
SMAC mimetics on NSAID-induced apoptosis and NSAID resistance. 
 
 81
5.2 RESULTS 
 
5.2.1 SMAC MIMETICS DO NOT AFFECT CELL VIABILITY 
 
The critical role of SMAC in NSAID-induced apoptosis suggested that 
manipulation of the SMAC pathway may improve the effects of NSAIDs.  The 
requirement of the AVPI domain for SMAC function prompted us to test whether 
pharmacologic agents that mimic this domain can enhance NSAID-induced apoptosis.  
Small molecule SMAC mimetic compounds have proven to be potent therapeutic 
agents that work either as single agents or in combination with another 
chemotherapeutic drug to induce a robust cellular apoptotic response at sub-
micromolar concentrations.   
Initial studies indicated that treatment of HCT116 cells with various doses of 
sulindac resulted in strong inhibition of cellular metabolic activity and growth at 
concentrations not sufficient to induce apoptosis (Figure 5.1A).  The effects of C3, a 
small molecule mimic of the AVPI residues of SMAC, and its control compound C4, 
which differs from C3 by a single methyl group, were subsequently tested in a similar 
assay [131].  In agreement with the published reports indicating apoptosis-specific 
effects of SMAC mimetic compounds, no significant differences in cell viability 
between control and active compounds administered in combination with sulindac 
were observed (Figure 5.1B). 
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Figure 5.1  SMAC mimetics do not affect cell growth and metabolic activity. 
A, Dose response to sulindac.  HCT116 cells were treated with the indicated 
concentrations of sulindac for 48 hours.  Loss of cell viability was determined by 
MTS colorimetric assay. 
B, Effect of SMAC mimetics on cell viability.  HCT116 cells were treated with 
NSAIDs at the indicated concentrations of sulindac alone or together with 100 nM 
control (C4) or test (C3) SMAC mimetic compounds for 48 hours.  Loss of cell 
viability was determined by MTS colorimetric assay. 
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5.2.2 SMAC MIMETICS POTENTIATE NSAID-INDUCED 
APOPTOSIS IN COLON CANCER CELLS 
 
It was previously shown that C3, but not C4, at nanomolar concentrations can 
sensitize human cancer cells to TRAIL or TNF-α–induced apoptosis [131].  In order 
to maximize the potential sensitizing effects of SMAC mimetic compounds, the 
response of colon cancer cells to reduced doses of NSAIDs was initially established 
(Figure 5.2).  According to the level of apoptosis induced by various doses of 
sulindac and indomethacin in different colon cancer cell lines, a single dose of each 
drug was picked that induced approximately 30% apoptosis (Figure 5.2).  SMAC 
mimetics have shown single agent toxicity in several cell lines.  Treatment with 
SMAC mimetic compounds alone, even at micromolar concentrations, did not have 
any growth inhibitory or apoptotic effects on colon cancer cells (Figure 5.3 and data 
not shown).  However, only 100 nmol/L of C3 was sufficient to markedly enhance 
NSAID-induced apoptosis in HCT116 cells, with the percentage of apoptotic cells 
increasing from 32% to 61% and from 22% to 59% after treatment for 48 hours with 
100 μmol/L sulindac and 250 μmol/L indomethacin, respectively (Figure 5.3).  In 
contrast, the control C4 compound did not have any effect on apoptosis (Figures 5.3 
and 5.4).  Similar observations were also made in HT29 and DLD1 colon cancer cells 
(Figure 5.3).  To verify these results, the analysis of an independent set of active and 
control SMAC mimetic compounds, GT-T and GT-C, demonstrated similar results 
(Figures 5.3 and 5.4). 
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Figure 5.2  Dose response to different NSAID concentrations. 
HCT116 cells were treated with NSAIDs at the indicated concentrations with or 
without 100 nmol/L control (C4 or GT-C) or test (C3 or GT-T) SMAC mimetic 
compounds for 48 hours.  Apoptosis induction was determined by nuclear staining. 
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Figure 5.3  SMAC mimetics sensitize colon cancer cells to NSAID-induced 
apoptosis. 
HCT116, HT29, and DLD1 colon cancer cells were treated with NSAIDs with or 
without 100 nmol/L control (C4 or GT-C) or test (C3 or GT-T) SMAC mimetic 
compounds for 48 hours.  Apoptosis induction was determined by nuclear staining. 
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Figure 5.4  SMAC mimetics potentiate NSAID-induced apoptosis. 
Representative fluorescence images of nuclei in Hoechst-stained cells.  Healthy cells 
contain nuclei with characteristic rounded shape and uniform staining, while 
apoptotic cells contain fragmented nuclei with condensed chromatin. 
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Analysis of apoptosis using Annexin V/propidium iodide staining confirmed 
that NSAID-induced apoptosis is enhanced by the active C3 or GT-T compound but 
not by the control C4 or GT-C compound (Figure 5.5).  Furthermore, colony 
formation assay results showed that combinations of NSAIDs with the active 
compounds were much more effective in inhibiting long-term survival of HCT116 
and HT29 cells compared with NSAIDs alone or their combinations with the control 
compounds (Figure 5.6).  Over 50% of the cells that could not be killed by sulindac or 
indomethacin alone were eliminated by the combination with C3 or GT-T (Figure 
5.6).  These results showed strong cooperative effects of NSAIDs and SMAC 
mimetics in killing colon cancer cells. 
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Figure 5.5  SMAC mimetics potentiate NSAID-induced apoptosis. 
HT29 colon cancer cells were treated with NSAIDs at the indicated concentrations 
with or without 100 nmol/L control (C4 or GT-C) or test (C3 or GT-T) SMAC 
mimetic compounds for 48 hours.  Apoptosis induction was analyzed by Annexin 
V/PI staining.  The percentage of apoptosis represents Annexin V/PI double-positive 
population.   
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Figure 5.6  SMAC mimetics potentiate inhibition of clonogenic survival. 
Long-term cell viability was assessed by colony formation assay following treatment 
with NSAIDs for 48 hours alone or in combination with 100 nmol/L control (C4, GT-
C) or active (C3, GT-T) SMAC mimetic compounds.  Top, representative pictures of 
cell colonies; bottom, quantitation of colony numbers. 
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5.2.3 SMAC MIMETICS OVERCOME NSAID RESISTANCE IN 
SMAC-KO AND BAX-KO CELLS 
 
We also looked at the effect of SMAC mimetics in SMAC-KO and BAX-KO 
cell lines, derived from the HCT116 cell line, which exhibit a potent and nearly 
complete resistance to apoptosis induced by NSAIDs, respectively.  The majority of 
HCT116 cells surviving from NSAID treatment contain BAX mutations and are 
defective in SMAC release [71, 99].  Acquired NSAID resistance was found to be 
associated with overexpression of anti-apoptotic Bcl-2 family proteins [151, 152].  
Because SMAC functions downstream of BAX and other Bcl-2 family members, we 
asked whether manipulating SMAC can restore NSAID sensitivity in NSAID-
resistant colon cancer cells that are deficient in BAX or SMAC.  It was shown that 
cytosolic, but not mitochondrial, SMAC can bypass the requirement of activating 
Bcl-2 family proteins to activate caspases [144, 146].  We therefore transiently 
transfected a cytosolic SMAC expression construct into BAX-KO cells (Figure 5.7), 
which are completely resistant to NSAIDs even at very high concentrations [71].  To 
maximize the apoptotic effect so that molecular markers of apoptosis could be 
analyzed, we used a higher concentration of sulindac (200 μmol/L) or indomethacin 
(800 μmol/L) than those used for other cell lines to treat BAX-KO cells.  We found 
that sulindac-induced apoptosis was indeed restored by the cytosolic SMAC in BAX-
KO cells (Figure 5.7).   
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Figure 5.7  SMAC overexpression restores NSAID sensitivity in BAX-KO cells. 
BAX-KO cells were transfected with the cytosolic SMAC expression construct (p-
cSMAC) or control empty vector.  Left, the expression of Flag-tagged cytosolic 
SMAC 24 hours after transfection was confirmed by Western blotting.  Right, cells 
were treated with 200 μmol/L sulindac for 48 hours.  Apoptosis was analyzed by 
nuclear staining. 
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Remarkably, the active SMAC mimetic compounds C3 and GT-T, but not the 
control compounds C4 and GT-C, also restored apoptosis induced by sulindac or 
indomethacin in BAX-KO and SMAC-KO cells (Figure 5.8).  These results were 
confirmed by analysis of apoptosis using Annexin V/propidium iodide staining 
(Figure 5.9).  They suggest that activation of the apoptotic pathway by SMAC or 
SMAC mimetics can overcome NSAID resistance in colon cancer cells. 
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Figure 5.8  SMAC mimetics restore NSAID sensitivity in SMAC-KO and BAX-
KO cells. 
SMAC-KO and BAX-KO cells were treated with 100 nmol/L control (C4 or GT-C) or 
test (C3 or GT-T) SMAC mimetic compounds alone or in combination with sulindac 
or indomethacin at indicated concentrations for 48 hours.  Apoptosis was analyzed by 
nuclear staining. 
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Figure 5.9  SMAC mimetics restore apoptosis in SMAC-KO and BAX-KO cells. 
SMAC-KO and BAX-KO cells were treated with sulindac or indomethacin at indicated 
concentrations alone or in combination with 100 nM control (C4 or GT-C) or test (C3 
or GT-T) SMAC mimetic compounds for 48 hours.  Apoptosis induction was 
analyzed by Annexin V/PI staining.  The percentage of apoptosis represents Annexin 
V/PI double-positive population.   
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5.2.4 EFFECTS OF SMAC MIMETICS DEPEND ON CASPASE-3 
AND INVOLVE CYTOCHROME C RELEASE 
 
We then investigated the mechanisms by which SMAC mimetics potentiate 
NSAID-induced apoptosis.  Since these compounds were designed to mimic the 
function of active SMAC in releasing caspases from inhibitory complexes with IAPs, 
we looked at whether SMAC mimetics regulated NSAID-induced activation of the 
caspase cascade.  As previously, reduced doses of NSAIDs were used to ascertain the 
sensitization effect of SMAC mimetics on NSAID-induced apoptosis.  Treatment 
with 100 μmol/L sulindac failed to induce robust caspase-3 and caspase-9 activation 
in HCT116 cells (Figure 5.10), consistent with the low level of apoptosis induced by 
sulindac at this concentration (Figures 5.2 and 5.3).  However, in combination with 
SMAC mimetic compounds, 100 μmol/L sulindac strongly induced accumulation of 
active caspase-3 and caspase-9 (Figure 5.10).  Although sulindac, even at 200 μmol/L 
concentration, could not induce caspase processing in BAX-KO cells, SMAC 
mimetics rescued caspase-3 and caspase-9 activation in these cells (Figure 5.11).  In 
agreement with the regulation of cytochrome c release by SMAC, treatment of 
HCT116 cells with sulindac combined with the active SMAC mimetics markedly 
enhanced cytochrome c release in HCT116 cells and also restored cytochrome c 
release in BAX-KO cells (Figures 5.10 and 5.11). 
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Figure 5.10  SMAC mimetics enhance caspase activation and cytochrome c 
release. 
HCT116 cells were treated with 100 μmol/L sulindac alone or in combination with 
100 nmol/L control (C4) or test (C3) SMAC mimetic compounds.  Top, caspase-3 
and caspase-9 activation was analyzed by Western blotting; bottom, cytosolic fraction 
was isolated from treated cells, and cytochrome c release was determined by Western 
blotting. 
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Figure 5.11  SMAC mimetics rescue caspase activation and cytochrome c release 
in BAX-KO cells. 
BAX-KO cells were treated with 200 μmol/L sulindac alone or in combination with 
100 nmol/L control (GT-C) or test (GT-T) SMAC mimetic compounds for 48 hours.  
Top, caspase-3 and caspase-9 activation was analyzed by Western blotting; bottom, 
cytosolic fraction was isolated from treated cells, and cytochrome c release was 
determined by Western blotting. 
 
 
 98
To test whether the effects of SMAC mimetics require caspase-3 activation, 
caspase-3 siRNA was transfected into cells before the combination treatment.  
Caspase-3 knockdown resulted in a significant reduction of apoptosis in the cells 
treated with the combinations of sulindac and SMAC mimetics, which was much 
more pronounced than the reduction of apoptosis seen in the cells treated with 
sulindac alone (Figure 5.12A), indicating that the sensitizing effects of the SMAC 
mimetics are at least in part mediated by caspase-3.  Furthermore, caspase-3 
knockdown also led to attenuation of cytochrome c release induced by the 
combination of sulindac and SMAC mimetics (Figure 5.12B).  These results 
suggested that SMAC mimetics potentiate NSAID-induced apoptosis and overcome 
NSAID resistance by promoting caspase-3 activation, thereby enhancing cytochrome 
c release.  
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Figure 5.12  Effect of caspase-3 knockdown on sensitization by SMAC mimetics. 
A, HCT116 cells were transfected with control scrambled or caspase-3 siRNA for 24 
hours and treated with 100 μmol/L sulindac.  Apoptosis induction was determined by 
nuclear staining 48 hours after sulindac treatment. 
B, HCT116 cells were treated with 100 μmol/L sulindac alone or in combination with 
100 nmol/L control (GT-C) or test (GT-T) SMAC mimetic compounds for 24 hours.  
Cytosolic fractions were isolated from treated cells, and cytochrome c release was 
determined by Western blotting 
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5.2.5 ESTABLISHING STABLE REPORTER COLON CANCER 
CELL LINES FOR FUTURE STUDIES OF SMAC MIMETICS 
IN ANIMAL MODELS 
 
Having demonstrated the sensitizing effect of SMAC mimetics on apoptosis 
induced by NSAIDs in a panel of colon cancer cell lines, the efficacies of these 
compounds need to be established and validated in future animal studies.  One 
method of studying the effect of a particular chemotherapy treatment on physiological 
tumor growth and development involves the establishment of xenograft tumors based 
on human cancer cell lines in nude mice that lack a functional immune system and 
therefore do not initiate a host-versus-graft response to human cells.  The xenograft 
tumor model can be further enhanced by using cancer cells with stable expression of 
luciferase enzyme.  Luciferases constitute a diverse group of unrelated enzymes 
acting upon chemically different luciferins and employ a variety of cofactors that are 
functionally classified as special types of oxygenases optimized for light emission 
[153].  These enzymes catalyze the oxidation of a luciferin substrate coupled to 
generation of energy-rich peroxidic intermediates, whose spontaneous decomposition 
results in emission of a photon of visible light with high efficiency [153].  The 
advantages of using bioluminescence to study tumor cells include non-invasive and 
real-time tumor monitoring capabilities within a living organism.  Data produced is 
both quantitative and qualitative, and multiple events may be examined within the 
same host. 
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NSAID-sensitive and NSAID-resistant cell lines were co-transfected with 
linearized pGL3 control plasmid and linearized pcDNA 3.1(+) G418 selection 
plasmid (Figure 5.13A).  The analysis of individual clones from each cell line 
revealed several orders of magnitude difference in luciferase activity (data not 
shown).  Since a certain basal level of luciferase activity is required to detect the 
bioluminescence signal from implanted tumor cells, the activity of luciferase in 
representative individual clones was verified under conditions resembling the 
bioluminescence analysis in live animals.  Detection of luciferase-mediated 
bioluminescence using a Xenogen IVIS 200 imaging system revealed a minimum 
signal strength that is required for animal studies (Figure 5.13B).  Using this criteria, 
several confirmed stable clones were selected for future mouse xenograft studies to 
establish luciferase-tagged human colon cancer tumors in immuno-deficient nude 
mice.  The response of the tumors to sulindac treatment alone or in combination with 
SMAC mimetic compounds will be tracked by quantifying tumor-specific luciferase 
activity.  Whole animal bioluminescence imaging will be performed on an IVIS 200 
imaging system available at the Small Animal Imaging Core. 
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Figure 5.13  Luciferase expression in colon cancer cell lines. 
A, Isolation of stable clones with high luciferase activity.  HCT116 wild-type, BAX-
KO, and SMAC-KO cells were co-transfected with linearized pGL3 Control plasmid 
and linearized pcDNA 3.1(+) G418 selection plasmid.  Whole-cell lysates were 
collected from 24-well plates and incubated with LAR reagent.  Samples were 
immediately analyzed for luciferase activity using PerkinElmer Victor3 plate reader. 
B, Detection of luciferase activity in cultured clones.  Representative clones with 
different levels of introduced luciferase activity were incubated with luciferin and 
analyzed for luciferase activity using Xenogen IVIS 200 imaging system. 
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5.3 DISCUSSION 
 
 The results obtained from two independent sets of compounds showed for the 
first time that SMAC mimetics can greatly potentiate the anticancer effects of 
NSAIDs in both short-term apoptotic and long-term clonogenic survival assays.  
Other studies have described similar effects of SMAC and SMAC mimetics on 
chemotherapeutic drugs and irradiation [143, 144, 154, 155].  SMAC mimetics not 
only greatly enhanced the apoptotic effects of sulindac and indomethacin in colon 
cancer cells with different genetic backgrounds but also restored apoptosis in the 
NSAID-resistant SMAC-KO and BAX-KO cells.  The data on BAX-KO cells were 
obtained using higher concentrations of NSAIDs (200 μmol/L sulindac and 800 
μmol/L indomethacin) than those used for other cell lines.  When SMAC mimetics 
were combined with NSAIDs at lower concentrations (120 μmol/L sulindac and 500 
μmol/L indomethacin), we also detected ~10% apoptosis in BAX-KO cells (data not 
shown).  The mechanistic studies showed that SMAC mimetics enhanced NSAID-
induced caspase-3 activation and cytochrome c release, thereby promoting the feed-
back loop for full execution of NSAID-induced apoptosis.  Importantly, the effects of 
SMAC mimetics are caspase-3–dependent, suggesting that caspases play a major role 
in mediating this feed-back loop, also reinforcing that the sensitizing effects are not 
due to off-target activities of SMAC mimetics [131].  It will be of interest to test 
whether previously reported activities of SMAC mimetics also operate through 
similar feed-back mechanisms. 
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A recent study has demonstrated the possible role of TRAIL-DR5 death 
receptor in mediating sulindac-induced apoptosis in HCT116 cells [98].  Sulindac 
treated cells exhibited a marked induction of TRAIL-DR5 expression and subsequent 
ligand-independent death receptor signaling, ultimately resulting in activation of 
proximal caspase-8 and an associated caspase-8–dependent apoptosis signaling.  In 
agreement with these findings, the present study showed that Bid, a well established 
caspase-8 substrate, was cleaved in sulindac treated cells to generate the active tBid 
fragment that showed a strong mitochondrial localization.  As was noted earlier, the 
activation and mitochondrial translocation of Bid occurred to an equal extent in 
HCT116 cells as well as the BAX-deficient derivatives, supporting the observation 
that caspase-8 is activated in HCT116 cells and BAX-KO cells treated with NSAIDs 
(previous findings; data not shown).  Active tBid fragment promotes BAX 
homooligomerization and BAX-dependent cytochrome c release by interacting with 
Bcl-2/Bcl-XL at the mitochondria and relieving their inhibition of BAX, or causing 
the conformational change in BAX through a direct interaction.  The data present in 
the present as well as previous studies indicate a critical role of BAX in NSAID-
induced apoptosis [71].  Therefore, two hypotheses are put forth aimed at explaining 
the ability of SMAC overexpression and SMAC mimetics to rescue apoptosis induced 
by NSAIDs in BAX-KO cells.  Since BAX-KO cells maintain the expression of Bak, a 
close relative of BAX, it can be postulated that the high doses of NSAIDs induce the 
hyperactivation of TRAIL-DR5 receptor, and the resulting high level of caspase-8 
activity induces a strong accumulation of tBid that activates Bak, allowing Bak to 
drive the initial release of cytochrome c in place of BAX.  In the concurrent presence 
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of a strong, cytosolic SMAC activity, caspase-9 and caspase-3 can respond to the 
presence of cytochrome c alone without the requirement for release of endogenous 
SMAC from mitochondria.  The initial activation of caspase-3 can subsequently 
establish the positive feed-back loop, similar to HCT116 cells, and promote the 
induction of apoptosis in previously resistant cells.  Alternatively, caspase-8 can 
directly activate caspase-3; however, caspase-3 activation is inhibited by IAPs.   
Addition of exogenous SMAC or SMAC mimetics results in dissociation of IAPs 
from caspase-3, and NSAID-activated caspase-8 can now fully activate caspase-3.  
Caspase-3 acts through the feed-back mechanism to induce the release of cytochrome 
c, resulting in an activation of caspase-9 and a more potent activation of caspase-3, 
leading to apoptosis.  The validity of the proposed mechanisms behind the observed 
activity of SMAC mimetics in BAX-KO cells can be experimentally verified by 
studying the effects of knocking down caspase-8, Bid, and Bak expression. 
Extensive efforts have been made toward developing therapeutic agents 
through manipulation of apoptotic pathways [156].  For example, ABT-737, a 
compound that mimics the BH3 domains of Bcl-2 family proteins, has shown great 
promise in early preclinical studies [157].  However, manipulation of apoptotic 
pathways for chemoprevention has not been extensively explored.  Our results 
suggest that SMAC mimetics are potentially useful as sensitizers for NSAIDs and 
possibly for other chemopreventive agents by boosting their pro-apoptotic activities 
and also by restoring apoptosis in otherwise resistant neoplastic cells.  It is worth 
noting that the concentrations of SMAC mimetics were lower than the concentrations 
of NSAIDs used in our study by three orders of magnitude.  The side effects of 
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NSAIDs, presumably caused by high drug doses used in prevention studies, have 
presented a significant challenge for using these agents for cancer prevention [126].  
It is possible that combinations of NSAIDs with SMAC mimetics will help to 
enhance chemopreventive efficacy, while reducing dose and decreasing toxicity.  This 
possibility can be tested using animal models, such as establishing xenograft tumors 
in nude mice or administration of sulindac together with SMAC mimetic compounds 
in APCMin/+ mice that spontaneously develop intestinal polyps and carcinomas. 
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5.4 CONCLUSION 
 
In this study, we analyzed the effects of modulating the molecular events that 
occurred during NSAID-induced apoptosis by small molecule SMAC mimetics, 
designed to recapitulate the function of the AVPI domain of SMAC in inducing the 
dissociation of caspase-IAP complexes.  As has been reported in the majority of 
human cancer cell lines derived from solid tumors, SMAC mimetics failed to inhibit 
cell viability and induce apoptosis as single agents.  Analysis of SMAC mimetic 
activity in combination with NSAIDs indicated a powerful sensitizing effect that was 
observed in multiple colon cancer cell lines.  The combination treatment of NSAIDs 
and SMAC mimetics invoked a potent apoptosis induction and inhibition of 
clonogenic potential at IC30 NSAID concentrations, suggesting a therapeutically 
relevant treatment regimen with enhanced induction of cancer cell death and reduced 
side effects stemming from NSAID-mediated inhibition of protective COX-1 
activities.  The sensitization of cancer cells to NSAID-induced apoptosis by SMAC 
mimetics was characterized by enhanced caspase activation and release of 
cytochrome c.  The resistance to NSAID-induced apoptosis normally observed in 
BAX-KO and SMAC-KO cells was alleviated by SMAC mimetics, confirming the 
positive effect of ectopic SMAC overexpression on apoptosis induced by NSAIDs in 
BAX-KO cells.  The rescue of apoptosis in NSAID-resistant cells was similarly 
characterized by the appearance of active caspase fragments and accumulation of 
cytosolic cytochrome c, suggesting that SMAC mimetics could bypass the apoptosis 
defects mediated by BAX and SMAC deficiency and act downstream of 
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mitochondria.  The activity of these compounds relied on caspase-3, as inhibition of 
caspase-3 by RNA interference significantly reduced the sensitizing effect of SMAC 
mimetics.  The validation of SMAC mimetics activity in small animals will be 
addressed by monitoring spontaneous cancer formation in APCMin/+ mice, as well as 
the analysis of xenograft tumor response in nude mice, facilitated by the development 
of luciferase-expressing human colon cancer cell lines that allows the use of 
bioluminescence detection methods. 
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APPENDIX:  GLOSSARY OF APOPTOSIS TERMS  
 
AIF Apoptosis-inducing factor 
Apaf-1 Apoptosis activating factor-1 
Bak Bcl-2 antagonist/Killer 
BAX Bcl-2 associated X protein 
Bcl-2 B-cell lymphoma -2 
BH3 Bcl-2 Homology 3 
Bid Bcl interacting domain 
Bim Bcl-2 interacting mediator of cell death 
BIR Baculoviral inhibitor of apoptosis repeat 
CARD Caspase recruitment domain 
CARP Caspase associated RING-protein 
Caspase Cysteinyl aspartate-specific protease 
DED Death effector domain 
Diablo Direct IAP binding protein with low pl 
DISC Death inducing signaling complex 
FADD Fas Associated Death Domain 
IAP Inhibitor of apoptosis protein 
Mcl-1 Myeloid cell leukemia-1 
NF-κB Nuclear Factor Kappa B 
SMAC Second mitochondrial-derived activator of caspase 
PUMA p53 up-regulated modulator of apoptosis 
TRAIL Tumor necrosis factor-related apoptosis-inducing ligand 
XIAP X-linked IAP 
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